A 11C raclopride PET study of dopamine activity, pain perception and reward processes in patients with fibromyalgia by Ledermann, Katharina
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2015
A 11C raclopride PET study of dopamine activity, pain perception and
reward processes in patients with fibromyalgia
Ledermann, Katharina
Abstract: Unspecified
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: http://doi.org/10.5167/uzh-111346
Published Version
Originally published at:
Ledermann, Katharina. A 11C raclopride PET study of dopamine activity, pain perception and reward
processes in patients with fibromyalgia. 2015, University of Zurich, Faculty of Science.
A 11C RDFORSULGH PET 6WXG\ RI DRSDPLQH 
AFWLYLW\, PDLQ PHUFHSWLRQ DQG RHZDUG PURFHVVHV 
LQ PDWLHQWV ZLWK FLEURP\DOJLD 
Thesis, (cumulative) 
Presented to the Faculty of Arts and Social Sciences 
of the University of Zurich 
for the Degree of Doctor of Philosophy 
by Katharina Ledermann 
Accepted in the Autumn Term 2014 
on the Recommendation of the Doctoral Committee: 
Prof. Dr. Lutz Jäncke 
Prof. Dr. Chantal Martin Sölch 
Zürich, 2015 
Die vorliegende Arbeit wurde von der Philosophischen Fakultät der Universität Zürich im
Herbstsemester 2014 auf Antrag von Frau Prof. Dr. phil. Chantal Martin-Sölch und Herrn
Prof. Dr. rer. Nat. Lutz Jäncke als Dissertation angenommen.
Acknowledgements
I am thankful to so many people for all their support and contribution in helping me
finishing this work – I would like to thank all of them here.
First of all, I would like to express my deepest gratitude to my supervisor Prof. Chantal
Martin-Soelch who has been my supervisor and mentor since the beginning of this project.
Thank you for supporting and guiding me through all the stages of this work and during my
entire PhD time.
Further, I would like to express my sincerest gratitude to Prof. Josef Jenewein, M.D., Prof.
Haiko Sprott, M.D. and Prof. Gregor Hasler, M.D. for their expertise and their support. I
would also like to thank the members of my dissertation steering committee,  Prof.  Dr.  Lutz
Jäncke  and  Dr.  Jolanda  Schlumpf,  Ph.D.  My sincere  thanks  to  Prof.  Ulrich  Schnyder,  M.D.
for providing me with the opportunity to conduct the study for this work at the Department of
Psychiatry and Psychotherapy of the University Hospital Zurich and also for providing his
expertise and support even from abroad.
Special thanks to all staff members of the PET Center at the Department of Nuclear Medicine
of the University Hospital Zurich for their excellent work and motivation during these
experiments.
Last but not least, I wish to thank my friends and colleagues who provided me with all kinds
of  social  support  during  my entire  PhD time.  My most  personal  thanks  are  extended  to  my
family, my parents Marlene and Heinz Ledermann, my sister Sabine Müller and my
grandparents Ferdinanda and Manfred Mathis to whom this book is dedicated. Whenever I
needed support, I could count on you. I thank you for always being there, for your love and
encouragement throughout this project.
Summary
Findings suggest that pain and reward are mediated by similar neural pathways in the central
nervous  system  (CNS)  and  that  these  pathways  are  related  to  both  the  dopamine  (DA)  and
opioid system. While DA has well described roles in motivational states, reward processing
and motor functions, a role for dopaminergic neurotransmission in modulating pain
perception and natural analgesia has also been demonstrated. Striatal dopaminergic
neurotransmission has been found to be altered in chronic pain syndromes such as burning
mouth, atypical facial pain and Fibromyalgia syndrome (FMS).
FMS is a chronic, painful musculoskeletal disorder characterized by widespread pain,
disturbed non restorative sleep, fatigue, and cognitive alterations and an increased incidence
of depressive symptoms. The neuropathophysiology of FMS is still poorly understood. Based
on the proposition that a disruption of normal dopaminergic neurotransmission may make a
substantial contribution to the pathophysiology of FMS, the prevailing motive for this project
was to investigate the modulation of pain perception by DA in FMS patients compared to
healthy controls using the [11C] raclopride Positron Emission Tomography (PET) method.
Because chronic pain has been suggested to impair reward processing and because FMS is
often associated with depression - a condition in which the neural processing of rewards has
been shown to be disabled, we tested whether the dopaminergic responses to financial
rewards were impaired in FMS and whether this impairment could differentiate between FMS
patients with and without depression.
We investigated DA D2/D3 receptor availability at rest and subjective ratings of pain related
to the administration of painful thermal stimulation in 17 healthy subjects, 13 subjects
fulfilling the American College of Rheumatology (ACR) classification criteria for FMS
without psychiatric comorbidity, and 11 subjects meeting the ACR criteria for FMS and the
criteria for major depressive disorder (MDD) (Report 1). Additionally, we measured the
endogenous DA release associated with unpredictable monetary rewards during Bolus-plus-
Infusion [11C] raclopride PET scanning in the same population (Report 2).
Findings from report 1 surprisingly revealed no differences in striatal D2/D3 receptor
availability between FMS patients with and without co-morbid MDD compared to healthy
controls. Furthermore, different associations between D2/D3 receptor availability and pain
perception were found between FMS patients and healthy subjects. Our results suggested that
alterations in the dopaminergic system appear to be linked to pain sensitivity and secondly,
that depression could influence pain perception in FMS patients.
Report 2 provided evidence for increased DA release to unpredictable monetary rewards in
FMS patients compared to healthy controls which was more prominent in FMS patients with
co-morbid depression. These results suggested dysfunctional DA responses to monetary
rewards in FMS patients relative to healthy controls and that the dysfunctional reward
circuitry could be associated with co-morbid depression in the pathology of FMS.
This work presents compelling evidence for alterations in the dopaminergic system as well as
dysfunctional DA responses to monetary rewards in FMS. These findings provide further
insight into the neuropathophysiology of FMS by addressing common neural bases of FMS
and depression.
Zusammenfassung
Aktuelle Studienbefunde deuten auf eine ähnliche Verarbeitung von Schmerz und Belohnung
durch neuronale Bahnen des Zentralen Nervensystems (ZNS), welche beide mit dem
Dopamin- und dem Opiatsystem assoziiert sind. Gut dokumentiert ist eine Beteiligung
dopaminerger Prozesse an der Verarbeitung von Belohnungsreizen.
Hinsichtlich einer Beteiligung von Dopamin (DA) an der Schmerzregulation gibt es ebenfalls
einige Hinweise, wobei die genaue Rolle von DA bei der Schmerzwahrnehmung und
Nachlassen von Schmerzen noch unzureichend geklärt ist. Einige empirische Befunde, deuten
darauf hin, dass bei chronischen Schmerzpatienten, einschliesslich Patienten mit
neuropathischen Schmerzen und Fibromyalgie Syndrom (FMS) eine Dysfunktion zentraler
dopaminerger Funktionen vorliegt. FMS ist eine chronische schmerzhafte muskuloskelettale
Erkrankung, die durch weitverbreitete Schmerzen, Hyperalgesie, Morgensteifigkeit und eine
erhöhte Prävalenz depressiver Symptomatik gekennzeichnet ist. FMS ist unheilbar und bisher
nur schwer zu behandeln. Über die neuropathologischen Grundlagen von FMS gibt es
insgesamt noch viele Unklarheiten. Im Weiteren gibt es Hinweise für eine starke
Komorbidität zwischen FMS und depressiven Störungen wobei oftmals Anhedonie, die
reduzierte Fähigkeit angenehme Aktivitäten zu geniessen, ein Hauptmerkmal ist. Es wird
vermutet, dass Anhedonie auf neurochemischer Ebene mit einer Unterfunktion des
dopaminergen Systems in Zusammenhang mit der Verarbeitung von Belohnungsreizen
korreliert ist.
Das Hauptziel dieses Projektes war es die modulierende Funktion von DA in Bezug auf
Schmerzwahrnehmung mittels der [11C] Raclopride PET Methode bei Patienten mit FMS zu
untersuchen und mit einer gesunden Kontrollgruppe zu vergleichen. Ein weiteres Ziel bestand
darin, zu testen, ob es zwischen FMS Patienten mit und ohne komorbide Depressionen
Unterschiede in der DA Reaktion auf Belohnungsreize gibt, um ein besseres Verständnis
dafür zu erhalten, ob eine Änderung der neuronalen Reaktion auf Belohnung zur Bildung von
komorbiden depressiven Symptomen in FMS beiträgt.
Wir untersuchten die Verfügbarkeit der Dopamin D2/D3 Rezeptoren und die subjektive
Bewertung von thermal applizierten Schmerzreizen in 17 gesunden Probandinnen, 13
Fibromyalgiepatientinnen ohne psychiatrische Komorbidität, welche die
Klassifikationskriterien für Fibromyalgie gemäss den Kriterien des American College of
Rheumatology (ACR) erfüllten sowie 11 Frauen, welche die Fibromyalgiediagnose gemäss
den ACR Kriterien sowie zusätzlich die Kriterien einer Majoren Depression (MDD) erfüllten
(Artikel 1). Zusätzlich haben wir die endogene DA Ausschüttung in Bezug auf
unvorhersehbare monetäre Belohnungsreize während Bolus-plus-Infusion [11C] Raclopride
PET Scanning in den gleichen Studienteilnehmern untersucht (Artikel 2).
Die Ergebnisse des 1. Artikels konnten überraschenderweise keinen Unterschied in der
striatalen D2/D3 Rezeptorverfügbarkeit zwischen FMS Patienten mit und ohne komorbide
Depressionen im Vergleich zu gesunden Kontrollen zeigen. Jedoch konnten unterschiedliche
Assoziationen zwischen der D2/D3 Rezeptor Verfügbarkeit und der Schmerzwahrnehmung
zwischen FMS Patientinnen und gesunden Kontrollen nachgewiesen werden. Unsere
Ergebnisse deuten darauf hin, dass Änderungen im dopaminergen System mit der
Schmerzwahrnehmung assoziiert sein könnten und dass komorbide Depressionen einen
Einfluss auf die Schmerzwahrnehmung bei Fibromyalgie haben könnten.
Die Ergebnisse des 2. Artikels demonstrieren eine höhere Dopaminausschüttung als Reaktion
auf unvorhersehbare monetäre Belohnungsreize bei FMS Patientinnen als bei gesunden
Kontrollen. Die Dopaminausschüttung war bei FMS Patientinnen stärker ausgeprägt als bei
gesunden Kontrollen und zwischen den beiden FMS Gruppen stärker ausgeprägt bei FMS
Patientinnen mit komorbiden Depressionen als bei denjenigen Patientinnen ohne
Depressionen. Die Resultate des 2. Berichts belegen dysfunktionale DA Reaktionen in Bezug
auf unvorhersehbare Belohnungsreize bei Fibromyalgiepatienten und deuten auf ein
dysfunktionales Belohnungssystem, welches in Zusammenhang mit der
Neuropathophysiologie von Fibromyalgie und den komorbiden Depression stehen könnte.
Zusammengefasst präsentiert diese Arbeit eindeutige Hinweise für pathologische Änderungen
im dopaminergen System im Zusammenhang mit der Schmerzwahrnehmung sowie Hinweise
für dysfunktionale DA Reaktionen in Bezug auf monetäre Belohnungsreize bei
Fibromyalgiepatienten. Diese Befunde geben weitere Einblicke in die Neuropathophysiologie
von FMS durch den Untersuch der gemeinsamen neuronalen Grundlagen von Fibromyalgie
und Depression.
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Chapter 1
Outline of this thesis
This thesis is organized as follows: After a general introduction into the subject and
aims of this thesis, theoretical background information is provided in chapter 2. First, some
basic principles and properties of the human pain system are briefly outlined. Next,
Fibromyalgia syndrome (FMS) is presented by reviewing important findings with a particular
emphasis  on  altered  pain  modulation  and  pathogenesis  of  FMS.  Next,  the  role  of  the  basal
ganglia in nociception and pain is described including findings supporting an implication of
DA in pain and reward and alterations of pain-reward interactions with chronic pain. The
empirical work is described in chapters 3 and 4. The first study, Relation of Dopamine
Receptor 2 Binding to Pain Perception in Female Fibromyalgia Patients with and without
Depression – a [11C] Raclopride PET Study, is presented in Chapter 3 followed by the second
study, Increased Dopamine release to unpredictable Rewards in female Fibromyalgia
patients with co-morbid depression – a [11C] Raclopride Bolus plus Infusion PET study, in
Chapter 4. Chapter 5 provides a synopsis of this work and highlights the main limitations and
conclusions that can be drawn from these studies.
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General Introduction
To be i n  ph ysi cal  pai n  i s to f i n d  y ou r sel f  i n  a d i f fer en t r eal m -  a sta te of
bei n g u n l i k e an y  oth er , a m agi c m ou n tai n  as far  r em oved  f r om  th e
fam i l i ar  w or l d  as a d r eam scape. Usu al l y  pai n  su bsi d es, on e w ak es f r om  i t
as f r om  a n i gh tm ar e, tr y i n g to for get i t  as qu i ck l y  as possi b l e. Bu t w h at of
pai n  th at per si sts? Th e l on ger  i t  en d u r es th e m or e ex cr u ci at i n g th e ex i l e
becom es. Wi l l  you  ever  go h om e? You  begi n  to w on d er , h om e to you r
n or m al  bod y , th ou gh ts, l i fe? (M el an i e Th er n stor m , 2 0 1 0 ) 1
1 Melanie Thernstrom, The Pain chronicles: Cures, Myths, Mysteries, Prayers, Diaries, Brain Scans, Healing and
the Science of Suffering (New York: Farrar, Straus and Giroux; 2010, p.3)
Chronic widespread pain has been described in the literature since the 19th century
(Gamsa,  1994).  During  this  time,  the  concept  of  fibromyalgia  as  a  clinical  entity  we  know
today was probably unknown to most physicians. However, throughout history people have
reported illnesses with strikingly similar symptoms. One prominent example is the great
Mexican painter Frida Kahlo (1907-1954) who was without a doubt one of the most intense
and  emotive  artists  of  the  20th century. After a car accident at the age of 18, she suffered
severe, widespread pain and profound fatigue. Generalized pain and exhaustion accompanied
her for the rest of her life. To explain Frida’s chronic illness, Martinez-Lavin et al. (2000)
suggested that she suffered posttraumatic fibromyalgia. A drawing in Frida’s diary where she
depicts herself in pain with 11 arrows pointing to anatomical sites near the conventional
fibromyalgia tender points reinforces this diagnostic impression (Martinez-Lavin, Amigo,
Coindreau, & Canoso, 2000). Fibromyalgia syndrome (FMS) is characterized by persistent
widespread pain, stiffness and tenderness of the muscles, tendons and joints and by the
presence of tender points in well-defined anatomical areas (Wolfe, 2010; Wolfe, Smythe,
Yunus, Bennett, Bombardier, Goldenberg, Tugwell, & Campell, 1990). Disturbed, non-
restorative sleep, fatigue, and cognitive alterations, all symptoms inherent in chronic pain
disorders, are often a prominent feature of the clinical picture of FMS. The etiology of FMS
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remains unknown, but the exploration of the pathophysiology underlying FMS has become an
exciting field of inquiry as research groups all around the world strive to improve their
understanding of this mysterious disorder (Hauser et al., 2009).
Recent findings suggest that pain and reward are mediated by similar neural pathways
in the central nervous system (CNS) involving a complex network of subcortical and
prefrontal structures related to both the dopamine (DA) and the opioid systems that influence
each other on a neurobiological and motivational level (Borsook et al., 2007; Kut et al., 2011;
Leknes  & Tracey,  2008).  While  DA has  well  described  roles  in  motivational  states,  reward
processing and motor functions (for review see Berridge, Robinson, & Aldridge, 2009;
Salamone & Correa, 2012), a role for dopaminergic neurotransmission in modulating pain
perception and natural analgesia has also been demonstrated (for review see Wood, 2008).
Furthermore, striatal dopaminergic neurotransmission has been found to be altered in chronic
pain syndromes including higher DA D2 receptor availability in patients with neuropathic
pain and reduced presynaptic D2 receptor availability in patients with FMS (Hagelberg,
Forssell, Aalto, et al., 2003; Hagelberg, Forssell, Rinne, et al., 2003; Wood, Patterson, et al.,
2007). However, the exact role of DA in anti-nociception, the action or process of blocking
the detection of a painful stimulus by sensory neurons, and pain perception is still unknown.
Mood disturbances are reported to be common in patients with Fibromyalgia, with stated
prevalence rates of depression ranging between 30 and 80% (Thieme, Turk, & Flor, 2004).
Additionally,  there  is  a  large  body  of  evidence  showing  that  the  DA  system  is  impaired  in
major depressive disorder (MDD) and that the processing of rewarding information is affected
in this condition (Martin-Soelch, 2009; Willner, 2000). Anhedonia, defined as markedly
diminished interest or pleasure in all or almost all activities, is a hallmark of depression
(Marbach & Lund, 1981; Stieglitz, 2000) and it has been suggested that anhedonia could be
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related to a hypofunction of the DA system which could affect the neural processing of
rewarding information (Willner, 2000). Therefore it has been hypothesized that these
alterations of the cerebral reward system could contribute to the development of depression in
chronic pain (Borsook et al., 2007). Furthermore, recent evidence suggests that pain, in
particular long-term pain, might impair several aspects of reward processing (Becker, Gandhi,
& Schweinhardt, 2012; Loggia et al., 2014) but none looked at the precise role of DA in this
relation.
Based on the proposition that a disruption of normal dopaminergic neurotransmission may
make a substantial contribution to the pathophysiology of FMS (Wood, 2008), the aim of this
project was to investigate the relationship between DA and pain perception in FMS. Further,
because chronic pain has been suggested to impair reward processing and because FMS is
often associated with depression - a condition in which the neural processing of rewards has
been shown to be disabled, we tested whether the dopaminergic responses to financial
rewards were impaired in FMS and whether this impairment could differentiate between FMS
patients with and without depression. Therefore, the prevailing motive for this project that
was supported by the Swiss National Foundation (32003B_127629/1, PI Prof. Chantal
Martin-Sölch) was to investigate the modulation of pain perception by DA in FMS patients
compared to healthy controls using the [11C] raclopride Positron Emission Tomography (PET)
method. This method allows to directly and non-invasively monitor changes in synaptic DA
concentrations (Dewey et al., 1993). A second aim was to investigate whether the DA
response to rewarding stimuli could differentiate between FMS patients with and without co-
morbid depression in order to better understand the depressive symptoms often associated
with  FMS.  We  correlated,  on  the  one  hand,  DA  D2/D3  receptor  availability  at  rest  with
subjective ratings of pain related to the administration of painful thermal stimulation in 17
healthy subjects, 13 subjects fulfilling the American College of Rheumatology (ACR)
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classification criteria for FMS (Wolfe, Smythe, Yunus, Bennett, Bombardier, Goldenberg,
Tugwell, & Campell, 1990) without psychiatric comorbidity, and 11 subjects meeting the
ACR criteria for FMS and the criteria for major depressive disorder (MDD) (Stieglitz, 2000).
We compared the discriminative capacity, i.e., the individual’s capacity to discriminate
between lower and higher pain intensities, and the response criterion, i.e. the subject’s
tendency to report pain during noxious stimulation due to psychological factors. Ratios of
striatal region/cerebellum tissue radioactivity concentrations (SCR) were calculated as a
measure of D2/D3 receptor availability (Report 1). On the other hand, we measured the
endogenous DA release associated with unpredictable monetary rewards during Bolus-plus-
Infusion [11C]raclopride PET scanning in the same subjects (Report 2). Findings concerning
basic DA D2 receptor availability and subjective ratings of pain related to administration of
painful thermal stimulation are presented in Report 1. Results regarding endogenous DA
release associated with unpredictable monetary rewards are provided in Report 2. Our results
on the role of DA in pain perception and reward processes in FMS may have important
clinical implications for subjects affected with FMS and may provide relevant information for
future research on FMS.
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Chapter 2
Theoretical background
2.1 The human pain system
2.1.1 What is chronic pain? – a definition
Pain is a complex, bio-psycho-social phenomenon that develops from the interaction
of several neuroanatomical and neurochemical systems with several cognitive and affective
processes (Garland, 2012). The established definition of pain according to the International
Association  for  the  Study  of  Pain  (IASP)  is:  “An  unpleasant  sensory  and  emotional
experience  associated  with  actual  or  potential  tissue  damage,  or  described  in  terms  of  such
damage” (Bonica, 1979, p. 250). Under normal physiological conditions, pain serves as a
protective mechanism critical for survival (Julius & Basbaum, 2001). Not only do afferent
sensory inputs alert the organism to potential danger and enact mechanisms to move away
from harm, but in the event that pain is inflicted, endogenous analgesic systems may reduce
pain sufficiently for the organism to escape (Sandkuhler, 1996). When the pain becomes
chronic however, a pathological state exists that does not serve as a warning for further tissue
damage and generally is of no obvious advantage to the organism’s survival (Stein, 2013).
Chronic pain in turn is defined as pain that is present for more than 6 months or pain
that persists beyond the expected time for healing (Mersky, 1994). There is a long list of
chronic clinical pain conditions related to different medical conditions including but not
limited to arthritis, diabetes, migraine, fibromyalgia, cancer and previous trauma or injury
(Breivik, Collett, Ventafridda, Cohen, & Gallacher, 2006).
The International Association for the Study of Pain (IASP) (Mersky, 1994) classified
pain according to specific characteristics: (1) region of the body involved (e.g., abdomen,
lower limbs), (2) system whose dysfunction may be causing pain (e.g., nervous,
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gastrointestinal), (3) duration and pattern of occurrence, (4) intensity and time since onset, (5)
and etiology. Moreover, three classes of pain have been distinguished: (1) nociceptive pain,
(2) inflammatory pain associated with tissue damage and the infiltration of immune cells, and
(3) pathological pain which is a disease caused by damage to the nervous system (neuropathic
pain) or by its abnormal function (dysfunctional pain, like in fibromyalgia, irritable bowel
syndrome, tension type headache, etc.) (Woolf et al., 1998). In the following section, a brief
overview of the physiological basis of pain will be provided without excessive detail or
comprehensiveness despite being an area of expanding complexity.
2.1.2 Functional neuroanatomy and neurochemistry of pain
Basically, pain emerges in the periphery by hurting the cruciate ligaments during
sports or by tripping on a hot plate, or even worse, as a side effect of a more severe disease
like cancer or HIV. When noxious stimuli impinge on the body from external or internal
sources, information regarding the damaging impact of these stimuli on bodily tissues is
transduced through neural pathways and transmitted through the peripheral nervous system to
the central and autonomic nervous system. This form of information processing is known as
nociception (Garland, 2012). The nociceptive system is a self-contained sensory system
comprising peripheral sensory fibers connected to multiple spinal tracts and brain regions.
Pain stimuli are sensed by specialized nociceptors - a highly specialized subset of primary
sensory neurons that respond only to pain stimuli (McCleskey & Gold, 1999). The resulting
pain signal travels from the periphery to the spinal cord along an AG- or C-fiber. Because the
AG-fiber is thicker than the C-fiber, and is thinly sheathed in an electrically insulating material
(myelin), it carries its signal faster (5-30 m/s) than the unmyelinated C-fiber (0.5-2 m/s).
These sensory fibers modulate pain sensations that innervate all body tissues in order to
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respond to the most compelling dangers (e.g. heat, cold, mechanical pressure and chemical
stimuli) (Willis, 1985). Perception of pain occurs when stimulation of nociceptors is intense
enough to activate AG -fibers resulting in a subjective experience of a sharp, prickling pain
(Bishop, Landau, & Jones, 1958) - known as first pain. As stimulus intensity increases, C-
fibers are recruited, and the individual experiences an intense, burning pain that continues
after  the  cessation  of  the  stimulus  -  known  as  second  pain  (Ochoa  &  Torebjork,  1989).
Second pain is diffuse, prolonged and aversive and is the main component of pain associated
with chronic medical conditions. The central pathways for processing nociceptive information
start  at  the  spinal  cord.  The  AG- and C-fibers enter the spinal cord and synapse on second
order neurons in the substantia gelatinosa (laminae II and III of the dorsal horns of the spinal
cord). Activation of nociceptors is modulated by inflammatory and biomolecular influences in
the local extracellular environment (Loeser & Melzack, 1999). Subsequently, nociceptive
projection neurons in the spinal cord transmit information via the spinothalamic tract - the
largest tract receiving its input from the fibers of the contralateral dorsal horn - which
provides nociceptive information to thalamic nuclei as well as to primary (SI) and secondary
(SII) somatosensory cortices (Garland, 2012; Willis, 1985). From these nuclei, nociceptive
information is relayed to various cortical and subcortical regions including the amygdala,
hypothalamus, periaqueductal grey, basal ganglia, and regions of the cerebral cortex (for
review see Willis, 1985). Moreover, the insula and anterior cingulate cortex are consistently
activated when nociceptors are stimulated and activation in these regions is associated with
the subjective experience of pain (Coghill et al., 1994; Ploghaus et al., 1999). SI and SII are
cortical regions believed to be involved in sensory-discriminative aspects of pain as well as in
the anticipation of painful stimuli (Fernandez & Turk, 1992). Neuroimaging studies have
consistently demonstrated several brain areas as having a major role in pain processing, and
together these brain areas are commonly referred to as the “pain matrix” (Brooks & Tracey,
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2005; Kupers & Kehlet, 2006) (Figure 2). The neurochemistry of pain and central-peripheral
pain modulation is extremely complex comprising chemicals such as peptides (e.g.
bradykinin), neurotransmitters (e.g. serotonin, dopamine), lipids (e.g. prostaglandins), and
neurotrophins (e.g. nerve growth factor) resulting in the excitation of nociceptors and
transmission of afferent signals to the dorsal horn of the spinal cord (Garland, 2012).
Nociceptive signal transduction up the spinothalamic tract results in an elevated release of
norepinephrine from the locus coeruleus neurons projecting to the thalamus, which transmits
nociceptive information to the somatosensory cortex, hypothalamus and hippocampus
(Garland, 2012). Opioid receptors in the peripheral and CNS result in the inhibition of pain
processing and analgesia when stimulated by opiates or endogenous opioids such as
endorphin, encephalin or dynophin (Garland, 2012). The brain does not passively receive pain
information from the body, but actively regulates sensory transmission by exerting influences
on the spinal dorsal horn via descending projections from the medulla (Garland, 2012;
Heinricher, Tavares, Leith, & Lumb, 2009; Yaksh, 1987). Taken together, the study of the
neural mechanisms involved in the perception, transmission, representation, and regulation of
pain has indeed uncovered a complex neural system that integrates painful information
permitting the organism’s adaptation to potential bodily injury or tissue damage (Rainville,
Bushnell, & Duncan, 2001). A schematic displaying nociception, pain perception and the
behavioral response to pain in the human nervous system is presented in the following (Figure
1).
CHAPTER 2 25
Figure 1. A schematic of nociception, pain perception and the behavioral response to pain
in the human nervous system
Figure 1. A schematic of nociception, pain perception and the behavioural response to pain in
the human nervous system (adapted from Garland, 2012, p. 565). Additionally to the
somatosensory elements described above, pain perception involves a number of psychological
processes including attentional orientation to the painful sensation and its source, cognitive
appraisal of the meaning of the sensation, and the subsequent emotional psychophysiological
and behavioural reaction, which then feedback to influence pain perception.
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Figure 2. Schematic of ascending pathways, subcortical structures, and cerebral cortical
structures involved in processing of pain. PAG, periaquaeductal gray; PB, parabrachial
nucleus of the dorsolateral pons; VMpo, ventromedial part of the posterior nuclear complex;
MDvc, ventrocaudal part of the medial dorsal nucleus; VPL, ventroposterior lateral nucleus;
ACC, anterior cingulate cortex; PCC, posterior cingulate cortex; HT hypothalamus; S1 and S2
first and second somatosensory cortical areas; PPC, posterior parietal complex; SMA,
supplementary motor area; AMYG, amygdala; PF, prefrontal cortex (adapted from Price,
2000, p. 1770).
Figure 2 Schematic of ascending pathways, subcortical structures, and cerebral
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2.1.3 Physiological basis of pain perception
Modern concepts of pain processing are based on the spinal gate control theory
formulated by Melzack and Wall in 1965, which highlighted the modulation of incoming
sensory information at the spinal level (Melzack & Wall, 1965). Prior to this, the prevailing
view of pain processing was largely passive, consisting of a simple one-to-one relationship
between nociceptive input and pain experience. Melzack and Wall (Melzack & Wall, 1965)
suggested that the intensity and quality of pain were determined by both physiological and
psychological variables. Their gate-control model proposed that the transmission of pain-
related nerve impulses is modulated by a “gating” mechanism at the substantia gelatinosa
(lamina II and III) of the dorsal horn of the spinal cord. This mechanism is influenced by the
balance between large- and small-diameter nerve fiber activity, with small diameter fibers
(AE-fibers) facilitating transmission (i.e. opening the gate) and large-diameter fibers (AG- and
C-fibers) inhibiting transmission (closing the gate). According to Melzack and Wall (Melzack
& Wall, 1965), a central monitor must supervise the spinal output. If the output exceeds a
certain level, the gate would open and a pain sensation would be created. Further, they
postulated that modulation from cortical and subcortical structures acts upon the spinal gating
mechanism. The central gray plays an important role in these descending inhibitory
mechanisms, serving to close the gate. Subsequently, they extended the gate control theory by
differentiating between sensory-discriminative, motivational-affective, and cognitive-
evaluative aspects of pain. According to their extended model, sensory inputs are not the only
determinants of pain. Moreover, these authors suggested that psychological and behavioral
factors might have several routes of action in attenuating or enhancing pain perception. Even
if some physiological assumptions of the gate-control theory were revised, the gate-control
theory transformed the understanding of individual differences in the expression of pain.
Psychological processes were no longer seen as mere reactions to pain, but as mediators in the
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perception of pain. Factors influencing pain perception will be briefly mentioned in the next
section.
2.1.4 Factors influencing pain perception
Perception of pain is influenced by various factors including cognition, emotion,
mood, chemical or structural influences, context, genetics and central or peripheral
sensitization (Tracey, 2010). Although nociception is usually the cause of pain, it is neither
necessary  nor  sufficient  and  is  very  often  not  linearly  related  to  the  resulting  pain  (Tracey,
2010). This is because many factors influence nociceptive processing along the pathway from
the nociceptor to the spinal cord and brain (Tracey & Mantyh, 2007). Pain perception
involves several psychological processes, including attentional orienting to the painful
sensation and its source, cognitive appraisal of the meaning of the sensation, and the
subsequent emotional, psychophysical and behavioral reaction. Factors influencing pain
perception are schematically described in Figure 3.
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Figure 3. Schematic illustration of key brain regions involved in generating a pain experience
and a description of the various factors that influence the pain experience listed in the text
boxes. vmPFC, ventromedial prefrontal cortex; OFC, orbitofrontal cortex; NAc, nucleus
accumbens; Amy, amygdala; Hypo, hypothalamus; Hipp, Hippocampus; S2, secondary
somatosensory cortex; S1, primary somatosensory cortex; dlPFC, dorsolateral prefrontal
cortex; rACC, rostral anterior cingulate cortex; mACC, midanterior cingulate cortex (adapted
from Tracey, 2010).
Figure 3 Schematic illustration of key brain regions involved in generating a pain
experience and a description of the various factors that influence the pain experience
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2.2. Current findings on the neuropathology of FMS
2.2.1 Definition and Classification
Fibromyalgia syndrome (FMS) is a disorder characterized by chronic widespread pain,
joint stiffness and clinical symptoms that include cognitive and sleep disturbances and other
abnormalities such as increased sensitivity to painful stimuli, increased sensitivity to multiple
sensory modalities, and altered pain modulatory mechanisms and excessive symptom
reporting (Roizenblatt, Moldofsky, Benedito-Silva, & Tufik, 2001; Wolfe, Ross, Anderson,
Russell, & Hebert, 1995; Wolfe, Smythe, Yunus, Bennett, Bombardier, Goldenberg, Tugwell,
Campbell,  et  al.,  1990).  Part  of  what  makes  FMS such  a  controversial  disease  is  its  diverse
and complex list of symptoms. Patients with FMS are likely to have a history of headaches,
dysmenorrhea, temporomandibular joint disorder, chronic fatigue, irritable bowel syndrome
and other functional gastrointestinal disorders, interstitial cystitis/painful bladder syndrome,
endometriosis and other regional pain. Additional symptoms may include strange sensations
on the skin (paresthesias), prolonged muscle spasms, nerve pain, muscle twitching, palpations
and functional bowel disturbances (Silver & Wallace, 2002). FMS is also often associated
with cognitive dysfunctions characterized by impaired concentration, problems with short-
and long-term memory, short-term memory consolidation, cognitive overload and diminished
attention span (Buskila & Cohen, 2007; Leavitt, Katz, Mills, & Heard, 2002).
According to the American College of Rheumatology (ACR) Criteria for the
Classification of Fibromyalgia (Wolfe, Smythe, Yunus, Bennett, Bombardier, Goldenberg,
Tugwell, Campbell, et al., 1990), chronic widespread pain lasting at least three months in
combination with mild or great tenderness at 11 or more of 18 specific tender points
constitute the principal criteria for the diagnosis of FMS. Those classification criteria were
primarily intended for research purposes and tender points were found to be the most
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powerful discriminator, being able to separate FMS from other painful rheumatologic
disorders. A tender point is defined as an anatomic site where an individual complains of pain
when approximately 4kg of digital palpation is applied. The determined 18 tender point sites
are illustrated in Figure 4. As these criteria alone do not encapsulate the complexities of FMS,
Wolfe suggested in 2010 new ACR criteria (Wolfe, 2010) not requiring the presence of
tenderness, but rather a list of several other symptoms including fatigue, unrefreshing sleep,
and cognitive symptoms, as well as a mixture of other symptoms like headache, depression
and lower abdominal pain/cramping. The hallmark symptom remains widespread pain, and a
diagnosis of FMS requires this symptom. Because the defining symptom of FMS is widely
distributed pain, it is usually considered a pain disorder, at least in the rheumatology
communities. However, in other disciplines such as psychiatry, psychosomatic or general
medicine, FMS is often considered to be a symptom or psychosomatic disorder (Kroenke,
2007). A recent study evaluating FMS symptoms in light of the Diagnostic and Statistical
Manual-5 (DSM-5) criteria for Somatic Symptom Disorder (SSD) (American Psychiatric
Association,  2013)  found  that  FMS  patients  will  satisfy  criterion  A  for  distressing  somatic
symptoms and criterion B that symptoms are “disproportionate” or excessive (Wolfe, Walitt,
Katz, & Hauser, 2014).
In the following, the key features of the ACR classification criteria for FMS disease
including the location of the nine paired tender points are presented.
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2.2.2 Key features of the ACR 1990 classification criteria for Fibromyalgia
Table 1: Key features of the ACR 1990 classification criteria for Fibromyalgia (adapted and
modified from Wolfe, Smythe, Yunus, Bennett, Bombardier, Goldenberg, Tugwell, Campbell,
et al., 1990)
Tabelle 1 Key features of the ACR 1990 classification criteria for Fibromyalgia
Widespread pain Pain in the left/right side of the body, pain
above/below the waist must be present. In
addition, axial skeleton pain (cervical spine or
anterior chest or thoracic spine or low back) must
be present.
Tender points Pain, on digital palpation (4kg/cm2) applied over
4 seconds), must be present in at least 11 of the
following 18 specified tender points bilateral
sites; occiput, low cervical, trapezius,
supraspinatus, second rib, lateral epicondyle,
gluteal, greater trochanter, and knee.
Diagnosis Both above mentioned criteria must be satisfied.
Widespread  pain  must  be  present  for  at  least  3
months. The presence of a second clinical
disorder does not exclude the diagnosis of
fibromyalgia.
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Figure 4. Location of the nine paired tender points that comprise the 1990 American College
of Rheumatology criteria for fibromyalgia (Wolfe, Smythe, Yunus, Bennett, Bombardier,
Goldenberg, Tugwell, Campbell, et al., 1990).
2.2.3 Etiology of FMS
Depending  on  the  classification  criteria,  FMS  is  estimated  to  affect  2-8%  of  the
population (McBeth & Jones, 2007; Vincent et al., 2013; Wolfe et al., 1995) (3.4% for
women and 0.5% for men) and is one of the most frequent diagnoses in rheumatologic
practice (Vincent et al., 2013). It can develop at any age, including childhood, but most
studies indicate an onset between the ages of 45-60 and indicate an increase in prevalence
with age (Wolfe et al., 1995). The prevalence is similar in different countries, cultures and
ethnic groups; there is no evidence that FMS has a higher prevalence in industrialized
Figure 4 Location of the nine paired tender points
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countries  and  cultures  (McBeth  &  Jones,  2007).  Genetic  factors  may  explain  the  strong
familial predisposition to FMS and other chronic pain states (Arnold et al., 2004).
2.2.4 Comorbidities of FMS
Comorbidity of FMS and psychiatric conditions are frequent (Buskila & Cohen, 2007)
including depression, panic disorders, anxiety and post-traumatic stress disorder (PTSD)
(Buskila & Cohen, 2007). Depression is the most frequent psychiatric comorbidity in FMS
(Fietta, Fietta, & Manganelli, 2007). Approximately 30% of patients with FMS have major
depression at the time of diagnosis; the lifetime prevalence of depression is 74% compared to
60% for an anxiety disorder (Arnold et al., 2004; Giesecke et al., 2003). The high occurrence
of depression in FMS has led to consideration of common neuroanatomical and
pathophysiologic mechanisms of pain and depression which may explain the increased
susceptibility to pain complaints in depression and the high incidence of depressive symptoms
in FMS (Arnold et al., 2004).
2.2.5 Altered pain perception in FMS
In  addition  to  the  afore-mentioned  characteristics  of  FMS,  FMS  patients  show
abnormalities in pain perception, including increased sensitivity to multiple types of painful
stimuli, increased sensitivity to other sensory modalities, and alterations in pain modulatory
mechanisms (Ceko, Bushnell, & Gracely, 2012). The following paragraph provides a short
overview of the most important findings. Increased sensitivity to many types of painful
stimulation has been reported in FMS. This includes pressure at non-tender point sites
(Gracely, Petzke, Wolf, & Clauw, 2002), hot and cold pain (Berglund, Harju, Kosek, &
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Lindblom, 2002; Desmeules et al., 2003; Lautenbacher, Rollman, & McCain, 1994; Petzke,
Clauw, Ambrose, Khine, & Gracely, 2003), electrical stimulation and intramuscular
hypertonic saline injection (Wood, Schweinhardt, et al., 2007). This hypersensitivity in FMS
patients to painful stimuli has led some investigators to propose that FMS involves a hyper-
vigilance to pain and pain-associated information (Asmundson, Kuperos, & Norton, 1997;
Crombez, Eccleston, Van den Broeck, Goubert, & Van Houdenhove, 2004; Keogh, Ellery,
Hunt,  &  Hannent,  2001).  However,  recent  studies  revealed  that  the  hypersensitivity  to
unpleasant stimuli extends beyond the somatosensory pain system (Gonzalez et al., 2010;
McDermid, Rollman, & McCain, 1996) giving rise to the hypothesis of a generalized hyper-
vigilance to sensory stimuli in FMS (Gonzalez et al., 2010; Hollins et al., 2009; McDermid et
al., 1996).
Aberrant pain processing, which can result in chronic pain, may be the result of
several interconnecting mechanisms. A neural mechanism called central sensitization leads to
an amplification of neural signaling within the CNS eliciting pain hypersensitivity which
might explain why FMS patients present an expansion of the receptive fields of pain, along
with hypersensitivity to touch (English, 2014; Yunus, 2007). This could explain why these
patients would feel more pain than would be normally expected based on the degree of
nociceptive input (English, 2014; Yunus, 2007). Another pathophysiological process that
appears to be disturbed in FMS patients is the “wind-up” of central nociceptive processing of
C-fiber input to the spinal cord (Ceko et al., 2012). The phenomenon of “wind-up” was
introduced by Mendell and Wall (Mendell & Wall, 1965) and refers to the fact that repetitive
electrical stimulation of C-fibers leads to an enhanced conduction of pain signals to the brain,
resulting in a perceptual phenomenon of greater temporal summation of pain. Congruent with
this observation, some FMS patients showed increased temporal summation of pain and
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increased after-sensations at the termination of noxious stimulation (Staud, Vierck, Cannon,
Mauderli, & Price, 2001).
Functional brain imaging studies support psychophysical findings of increased pain
perception in FMS showing an augmentation of sensory processing throughout pain-related
brain regions (Burgmer et al., 2009; Cook et al., 2004; Diers et al., 2008; Diers et al., 2011;
Pujol et al., 2009; Staud, Craggs, Perlstein, Robinson, & Price, 2008). A number of
anatomical imaging studies in FMS patients revealed decreased brain grey matter in regions
associated with descending pain control circuitry and pain modulation (Schweinhardt, Sauro,
& Bushnell, 2008; Villemure & Bushnell, 2009; Wiech, Ploner, & Tracey, 2008).
Abnormalities in descending pain pathways comes from experimental testing of conditioned
pain modulation (Julien, Goffaux, Arsenault, & Marchand, 2005) and neuroimaging studies
demonstrating reduced connectivity of descending pain inhibitory networks (K. B. Jensen et
al., 2012). Consistent with the idea that pain modulatory systems may be disturbed in FMS,
FMS patients have shown abnormalities in neurochemical systems involved in pain control,
including the DA system (Wood, Schweinhardt, et al., 2007) and the forebrain opioid system
(Harris et al., 2007). The role of the DA system in pain perception in FMS will be discussed
further in a separate section since the role of the DA system in FMS constitutes a central
component of this thesis.
2.2.6 Pathogenesis of FMS
Controversy remains as to the cause and nature of FMS and the exact mechanisms of
FMS pain remain to be determined. Several factors appear to be involved in the pathogenesis
of FMS such as dysfunctions of the CNS and autonomic nervous systems, neurotransmitters,
hormones,  immune  system,  external  stressors,  psychiatric  aspects  and  others  seem  to  be
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involved (for review see Bellato et al., 2012). The involvement of the brain and the CNS in
the pathogenesis of this condition is supported by numerous functional neuroimaging studies
(for  review  see  Bellato  et  al.,  2012).  Descending  inhibitory  pain  pathways  also  seem  to  be
impaired in FMS, helping to exacerbate central sensitization (Staud et al., 2001; Watkins &
Maier, 2005; Watkins, Milligan, & Maier, 2001). This reduced inhibition of pain in
combination with the increased input of pain signals are considered the causes of hyperalgesia
found in FMS (Woolf, 2011).
Specific neurotransmitters possibly involved in the pathogenesis of FMS have also
been investigated. There is evidence for increases in the cerebrospinal-fluid (CSF), levels of
Substance P, glutamate, nerve growth factor and brain-derived neurotrophic factor and low
levels of serotonin, norepinephrine and DA - any of which could lead to inhibition of pain
transmission and augmented pain and sensory processing (Alnigenis & Barland, 2001;
Giovengo, Russell, & Larson, 1999; Hauser, Urrutia, Tort, Uceyler, & Walitt, 2013; T. S.
Russell & Percy, 1994; Vaeroy, Helle, Forre, Kass, & Terenius, 1988; Wood & Holman,
2009). Abnormalities in the hypothalamic-pituitary-adrenal (HPA) axis, autonomic nervous
system and immune system including reduced HPA activity with decreased cortisol
production both at baseline and in response to a variety of stressors (Yunus, 2012), and
flattened  diurnal  rhythm of  the  HPA axis  (McLean et  al.,  2005)  have  been  reported.  As  the
HPA axis is closely linked with the autonomic nervous system, sympathetic hyperactivity as a
component of the stress response that precipitates and perpetuates FMS symptoms has been
identified (Staud, 2008). Additionally, enhanced inflammatory activity, shown by elevated
serum levels of pro-inflammatory cytokines (e.g. TNF-Į, IL-1 and IL-6) have been
demonstrated in FMS (Bazzichi et al., 2007; Salemi et al., 2003; Wang, Moser, Schiltenwolf,
& Buchner, 2008). Alterations in neuron-glial cell relationships have been found to be
involved in the pathogenesis of chronic pain (Xie, Huo, & Tang, 2009) and are also suggested
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to  play  a  role  in  the  genesis  of  FMS  (Kadetoff,  Lampa,  Westman,  Andersson,  &  Kosek,
2012). Taken together, the CNS has been investigated extensively while research on
peripheral nervous involvement is less advanced (Blumenstiel et al., 2011) and an overall
concept of the impact of the peripheral nervous system on pain in FMS is missing. Recent
studies, however, function and morphology of small nerve fibers in patients with FMS were
investigated by quantitative sensory testing, pain-related evoked potentials and quantified
nerve-fiber density in skin punch biopsies, and compared with findings in patients with major
depression and healthy controls. (Uceyler & Sommer, 2013). The observed
neurophysiological and psychophysiological hypofunction was morphologically paralleled by
reduction in dermal unmyelinated nerve-fiber bundles, whereas myelinated nerve fibers were
spared, suggesting impaired small fiber function in FMS (Uceyler & Sommer, 2013). These
findings point towards a possible neuropathic nature of FMS pain, and the authors argued that
pain in FMS should be classified accordingly (Uceyler & Sommer, 2013).
2.2.7 Vulnerability factors for developing FMS
As FMS is frequently comorbid with mental disorders such as chronic fatigue
syndrome, PTSD, irritable bowel syndrome and depression, FMS has been characterized as a
“stress-related disorder” due to its onset and exacerbation of symptoms in the context of
stressful events (Hudson, Goldenberg, Pope, Keck, & Schlesinger, 1992). Stress may
therefore be an important precipitating factor in the development of FMS (Anderberg,
Marteinsdottir, Theorell, & von Knorring, 2000). However, the risk of developing FMS
symptoms is clearly affected by multiple factors. These include psychological distress (Ablin,
Buskila, & Clauw, 2009; Robinson, McBeth, & Macfarlane, 2004), social factors such as
socioeconomic status (Macfarlane, Norrie, Atherton, Power, & Jones, 2009), physical trauma
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(Jones et al., 2011), genetic susceptibility and aberrant pain-processing mechanisms (Ablin et
al., 2009; Clauw, 2009; Gupta et al., 2007). A systematic review reported significant
associations between FMS and physical and sexual abuse in both childhood and adulthood
(Hauser, Kosseva, Uceyler, Klose, & Sommer, 2011).
2.2.8 Treatment of FMS
FMS is best approached from a multidisciplinary perspective integrating
pharmacological (in particular antidepressants and neuromodulating antiepileptics) and
nonpharmacological treatment (importance of stress reduction, sleep, exercise) (Okifuji &
Hare, 2013). Pharmacological therapies can be helpful in alleviating some symptoms, but
patients rarely achieve meaningful improvements without adopting self-management
strategies. Several classes of drugs have strong evidence for efficacy in treating FMS (Hauser,
Petzke, & Sommer, 2010), including tricyclic compounds (amitriptyline, cyclobenzaprine;
Arnold, 2007), gabapentinoids (Tzellos et al., 2010), serotonin and norepinephrine reuptake
inhibitors (duloxetine; (Arnold et al., 2009), milnacipran (Geisser, Palmer, Gendreau, Wang,
& Clauw, 2011)), and y-hydroxybutyrate (I. J. Russell et al., 2011). Further, central
neurostimulatory therapies are in development that presumably stimulate brain structures
involved in pain processing showing promise for treating centralized pain states such as FMS
(Hargrove et al., 2012).
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2.3 Findings supporting the role of DA in pain and reward
2.3.1 The mesolimbic DA system
DA is a catecholamine neurotransmitter in the CNS described half a century ago
(Carlsson, 1959). It is best known for its role in motor control, cognition and the neural
processing underlying motivated and reward-related behavior (Kaasinen & Rinne, 2002;
Nieoullon, 2002). Accordingly, the role of DA is evident in the neurobiology and symptoms
of a myriad of neurological and psychiatric diseases, including Parkinson’s disease,
schizophrenia and addiction (Bernheimer, Birkmayer, Hornykiewicz, Jellinger, &
Seitelberger, 1973; Bernheimer & Hornykiewicz, 1965; Di Chiara & Bassareo, 2007). The
DA signaling across the brain involves several neuroanatomical pathways. One of them is the
mesolimbic  DA pathway comprised  of  neurons  that  project  from the  ventral  tegmental  area
(VTA)  of  the  midbrain  to  subcortical  structures,  such  as  the  nucleus  accumbens,  thalamus,
hippocampus, and amygdala (Le Moal & Simon, 1991).
Recent neuroimaging studies in healthy individuals have identified substantial overlap
between the network of brain regions most commonly implicated in pain processing
(Apkarian, Bushnell, Treede, & Zubieta, 2005) and regions that comprise the DA system
(Leknes & Tracey, 2008). There are five subtypes of DA receptors, designated D1 through D5
(Sibley, Monsma, & Shen, 1993). D2 and D3 receptors are expressed throughout the brain
with the highest concentration in the basal ganglia, globus pallidus, substantia nigra and
ventral tegmental area (Gurevich & Joyce, 1999). D3 receptors are largely absent in the
ventral tegmental area, but are expressed in the basal ganglia (most abundantly in the limbic
striatum), substantia nigra, globus pallidus and in the anterior and medial thalamic nuclei
(Suzuki, Hurd, Sokoloff, Schwartz, & Sedvall, 1998).
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2.3.2 The role of the basal ganglia in nociception and pain
The basal ganglia comprise multiple subcortical nuclei at the base of the forebrain
strongly interconnected with the cerebral cortex, thalamus and brainstem, as well as several
other  brain  areas.  They  consist  of  the  striatum  (nucleus  caudate,  putamen  and  core  of  the
nucleus accumbens), the external and internal segment of the globus pallidus, the subthalamic
nucleus, and the substantia nigra (Graybiel, 2000, 2005) (see also Figure 5). The globus
pallidus and substantia nigra can further be subdivided into smaller components that serve as
output structures of the basal ganglia (Alexander & Crutcher, 1990). The main input area of
the basal ganglia is the striatum, which receives synaptic input from cortical and subcortical
afferents such as dopaminergic projections from the substantia nigra and the VTA (Alexander
& Crutcher, 1990; Graybiel, 2000). The basal ganglia is associated with a variety of
functions: including execution of motor, cognitive and emotional activities (Graybiel, 2004).
Furthermore, preclinical studies support an involvement of the basal ganglia in pain
processing. Although not exhaustive, these preclinical studies comprise electrophysiology
(Bernard, Huang, & Besson, 1992; Chudler, 1998), analgesic effects of microinjections into
these  regions  (Tashev,  Belcheva,  Milenov,  &  Belcheva,  2001),  electrolytic  lesion  studies
(Saade, Shbeir, Atweh, & Jabbur, 1996), chemical lesions of dopaminergic terminals (Saade,
Atweh, Bahuth, & Jabbur, 1997; Takeda et al., 2005), activation of striatal dopamine system
producing analgesia in rats (Lin, Wu, Chandra, & Tsay, 1981) and imaging drug effects in
neuropathic rat models (Porro et al., 1999). Neuroimaging studies have added important
information on basal ganglia activation in conditions of acute and chronic pain using a
number of methods such as functional MRI (fMRI), pharmacological MRI,
morphometric/anatomical measures (diffusion tensor imaging and gray matter volumetric
analysis)  and  PET studies  that  allow whole  brain  evaluation  of  specific  circuits  (for  review
see Borsook, Upadhyay, Chudler, & Becerra, 2010). Activation in specific regions of the
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basal ganglia (putamen, globus pallidus, caudate nucleus, nucleus accumbens) responding to
noxious stimuli including thermal, mechanical, painful electrical and visceral pain have been
reported in acute pain (for review see Borsook et al., 2010). Increased activation in the globus
pallidus and putamen produced across multiple painful stimuli as well as a consistent
decreased activity in the caudate nucleus to mechanical, cold and heat stimuli has been shown
in chronic pain (Becerra, Harter, Gonzalez, & Borsook, 2006). Atrophy in a single cluster
encompassing the right insula, the right ventromedial prefrontal cortex (vmPFC) and right
nucleus accumbens has been shown in patients with complex regional pain syndrome (CPRS)
(Geha et al., 2008) suggesting that chronic pain may alter basal ganglia structure.
Additionally, findings suggest that basal ganglia loops integrate many aspects of pain
including the integration of motor, emotional, autonomic and cognitive responses to pain and
an analgesic role for dopaminergic neurotransmission within the basal ganglia in nociception
and pain has been described (Chudler & Dong, 1995). Taken together, alterations in activation
patterns  and  basal  ganglia  structure  show  an  involvement  of  the  basal  ganglia  in  acute  and
chronic pain. In the following, an illustration of the basal ganglia is presented to demonstrate
its  placement  in  the  human  brain.  The  next  section  discusses  the  role  for  dopaminergic
neurotransmission in the basal ganglia in nociception and pain.
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Figure 5 Illustration of the basal ganglia
Figure 5. Illustration of the basal ganglia adapted from Nieuwenhuys et al. 1981
(Nieuwenhuys R, Voogd J van huiizen c the human central nervous system: A synopsis and
Atlas. 2nd ed. Berlin Springer.).
2.3.3 The role of DA in pain and analgesia
Ample  evidence  from  animal  study  models  has  highlighted  how  DA  plays  a  critical
role in anti-nociception. These rodent studies demonstrated that DA suppresses pain behaviors
in response to phasic as well as tonic noxious stimuli of different modalities, including
thermal, mechanical, and chemical stimuli (Lapirot et al., 2011; Magnusson & Fisher, 2000;
Shimizu et al., 2004). This occurs primarily via activation of D2 (and likely D3) receptors in
such areas as the basal ganglia, including the ventral striatum/nucleus accumbens, in the
limbic cortex and the spinal cord (Shimizu et al., 2004). In humans, indirect evidence from
genetic  studies  as  well  as  studies  in  pain  patients  and  patients  with  syndromes  affecting
central  dopaminergic  function  (such  as  Parkinson’s  disease)  supports  a  role  of  DA  in  the
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processing of nociceptive stimuli (Brefel-Courbon et al., 2005; Jarcho, Mayer, Jiang, Feier, &
London, 2012; Treister et al., 2009). Furthermore, analgesic properties of drugs which
enhance DA neurotransmission such as for example Levadopa, an indirect dopaminergic
agonist used to treat Parkinson’s disease, reduces pain-related symptoms in patients with
Parkinson’s disease (Quinn, Koller, Lang, & Marsden, 1986), diabetic neuropathy (Ertas,
Sagduyu, Arac, Uludag, & Ertekin, 1998) or herpes zoster (Kernbaum & Hauchecorne, 1981).
Based on these lines of evidence, it has been hypothesized that DA has direct anti-nociceptive
effects (Hagelberg et al., 2004; Jarcho et al., 2012; Wood, 2008).
Accordingly, recent neuroreceptor studies using PET to evaluate dopaminergic
function have shed important insights on the role of DA in human pain experience. PET
studies with [11C] raclopride, a radiotracer that binds to D2-like DA receptors, have been used
to assess tonic levels of striatal DA under baseline conditions, and phasic DA release
associated with noxious stimulation. These studies revealed that healthy individuals with
lower levels of tonic DA release in the striatum, indexed by higher levels of radiotracer
binding under basal conditions, are more sensitive to noxious stimulation (Hagelberg et al.,
2002). Additionally, the role of D2 receptors in pain modulation has been studied by
Hagelberg et al. by determining the association between responses to experimental pain and
D2 receptor binding potential at baseline (Hagelberg et al., 2004; Hagelberg et al., 2002). A
significant negative correlation between cold pain threshold and D2 receptor binding potential
in the right putamen has been reported. Cold pain tolerance was inversely correlated with DA
D2 receptor binding potential in the right medial temporal cortex. Heat pain threshold had no
significant correlation with D2 binding potential in any of the regions, but the elevation of
heat pain threshold induced by conditioning cold pain was directly correlated with D2
receptor binding potential in the left putamen. A subsequent analysis compared subjects’
cutaneous heat pain threshold baseline D2 receptor binding potential and likewise found an
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inverse correlation between heat pain threshold and binding potential in the right putamen
(Martikainen et al., 2005). No association could be determined between striatal DA binding
potential and response to tactile stimulation, leading to the conclusion that the influence of
striatal D2 receptors on sensory thresholds is selective for pain modality. Scott et al. examined
the response of striatal DA in response to moderate sustained pain (i.e. hypertonic saline
infusion into the masseter (Scott, Heitzeg, Koeppe, Stohler, & Zubieta, 2006)). DA release
was observed in the dorsal caudate nucleus and putamen quantitatively associated with
individual variations in subjective sensory and affective ratings of pain. DA release in the
nucleus accumbens was exclusively associated with variations in emotional responses. This
study concluded that DA in the human basal ganglia is involved in response to pain and
contributes to individual variations in physical and emotional pain experience. Furthermore,
other  PET  studies  with  [11C] raclopride have revealed that DA neurotransmission in the
striatum increases during noxious stimulation, as indexed by decreased radiotracer binding
(Scott et al., 2006; Scott, Stohler, Koeppe, & Zubieta, 2007). In summary, several studies
have reported that DA D2/D3 receptors are involved in the regulation and perception of pain
in humans (Hagelberg et al., 2002; Martikainen et al., 2005; Pertovaara et al., 2004; Scott et
al., 2006; Wood, Schweinhardt, et al., 2007).
Evidence supporting the relationship between pain and function of the DA system in
the brain is also derived from studies with chronic pain syndromes. Such studies have
employed a variety of experimental techniques in groups of patients with different diagnoses
(e.g., burning mouth syndrome, atypical facial pain, restless legs syndrome, FMS, complex
regional pain syndrome (CRPS) or painful diabetic neuropathy (for review see Wood, 2008)).
More precisely, in burning mouth syndrome, striatal dopaminergic function using 6-[18F]
fluoro-L-DOPA PET found that these patients had significantly reduced fDOPA uptake in the
right putamen with a non-significant decrease on the left. Further, these patients demonstrated
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a significantly higher number of unoccupied D2 receptors in the left putamen with a lower
D1/D2 receptor ratio in the bilateral putamen (Jaaskelainen, Forssell, & Tenovuo, 1997;
Jaaskelainen et al., 2001). No difference in presynaptic DA synthesis or D1 receptor binding
was observed in patients with atypical facial  pain (Wood, Patterson, et  al.,  2007).  However,
these patients exhibited a non-significant tendency towards increased D2 receptor availability
in the left putamen and a bilateral reduction in the D1/D2 ratio in the putamen. In summary,
these  findings  demonstrate  that  patients  with  chronic  pain  conditions  are  associated  with
alterations in the striatal dopaminergic system characterized by reduced presynaptic activity
of striatal DA neurons and changes in DA D2 receptor availability.
2.3.4 The role of DA in the pathophysiology of FMS
The first hint in the medical literature of a connection between FMS and DA was
provided by Russell et al., who in 1992 reported lower concentrations of metabolites of DA,
norepinephrine, and serotonin in the CSF of patients with FMS in comparison to healthy
controls (I. J. Russell, Vaeroy, Javors, & Nyberg, 1992). Indirect pharmacological evidence of
dopaminergic  dysfunction  in  FMS was  first  provided  by  Malt  et  al.  who reported  that  FMS
patients  had  an  augmented  prolactin  release  in  response  to  a  single  challenge  dose  of
buspiron, a D2-Antagonist, in comparison with controls (Malt, Olafsson, Aakvaag, Lund, &
Ursin, 2003) suggesting that FMS may be characterized by increased sensitivity or density of
DA D2 receptors. The prolactin response to buspirone has been explained through dopamine
antagonistic effect at the level of the pituitary gland (Meltzer, Simonovic, Fang, & Gudelsky,
1982).
Finally, studies using PET have provided direct evidence of a disruption in
dopaminergic neurotransmission in patients with FMS. The first, using 6-[18F] fluoro-L-
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DOPA to determine presynaptic DA activity of dopaminergic neurons, demonstrated a
significant reduction in uptake in dopaminergic centers of the mid-brain (i.e. ventral
tegmental area and substantia nigra) and in multiple regions of the pain neuromatrix wherein
DA plays a role in natural analgesia, including the thalamus, insula, and cingulate cortex
(Wood, Schweinhardt, et al., 2007). A subsequent study evaluated DA release associated with
noxious stimulation in FMS patients in comparison with matched healthy controls. Tonic pain
caused by the infusion of hypertonic saline resulted in DA release into the striatum in healthy
females that correlated with subjective ratings of pain intensity (Wood, Schweinhardt, et al.,
2007). In contrast, FMS patients demonstrated profound disruption of DA release with painful
stimulation. Furthermore, these findings provide compelling evidence for the proposition that
FMS could be associated with a disruption of dopaminergic neurotransmission. However the
exact nature of this relationship and its role in FMS remains unclear.
2.3.5 The role of DA in the processing of reward information
Rewards can broadly be defined as desirable outcomes that serve to influence behavior
and have been posited to serve various functions, such as inducing feelings of pleasure,
eliciting exploratory or approach behavior, and increasing the frequency and intensity of
behaviors that lead to rewards (Schultz, 2000). The identification of the brain’s reward circuit
can be traced back to the pioneering work of Olds and Milner (1954), who demonstrated that
the  placement  of  electrodes  at  particular  areas  of  the  brain  in  rats  could  elicit  repetitive
behavioral responses to trigger electrical stimulation. This seminal finding, which first
mapped positive reinforcement to specific brain sites, initiated decades of research aimed at
teasing apart the neural underpinnings of how a reward can shape an organism’s behaviors or
decisions. There is a large body of evidence that regions associated with the mesolimbic DA
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pathway are involved in the neural processing of reward information in humans and in
animals including the prefrontal cortex, striatum, VTA, ventral pallidum, hypothalamus,
amygdala, and habenula (Haber & Knutson, 2010). Interconnected by transmitter systems
involving DA, serotonin, glutamate, GABA and opioids have been incorporated into a
conceptual “reward circuit” (Koob, Rassnick, Heinrichs, & Weiss, 1994). Reward processing
is not a homogeneous entity and encompasses several regions and functions. Findings from
neuroimaging  studies  indicate  that  the  orbitofrontal  cortex  (OFC),  amygdala  and  ventral
striatum are implicated in reward prediction (Gottfried, O'Doherty, & Dolan, 2003). In this
vein, it has been shown that the ventral striatum and amygdala responded to predictors of
reward specifically, but not to reward itself after a learning process (O'Doherty, Deichmann,
Critchley, & Dolan, 2002; Schultz, 2000). Learning of value predictions would take place in
the ventral putamen and OFC through the activation of DA neurons facilitating the
development of plasticity between sensory and reward representations in these regions
(McClure, Berns, & Montague, 2003; Schoenbaum, Roesch, Stalnaker, & Takahashi, 2011;
Tremblay  &  Schultz,  1999).  Finally,  the  striatum,  specifically  the  dorsal  part,  might  be
implicated in stimulus-response learning as evidenced by activation of the dorsal striatum
when there is a contingency between response and reward (Elliott, Newman, Longe, &
William Deakin, 2004; Everitt et al., 2008; Volkow, Fowler, Wang, Swanson, & Telang,
2007). Rewards are also closely related to motivation defined by their capacities to trigger
pleasant emotions to continue a behavior, by inducing subjective feelings of pleasure
(O'Doherty, 2004). Reward may also act as positive reinforcement by increasing the
frequency and intensity of behavior that leads to the acquisition of goal objects, as described
in classical and instrumental conditioning procedures. Some studies investigated the direct
implication of DA in response to rewards using the [11C]raclopride  PET  method.  As  [11C]
raclopride binding is thought to reflect endogenous DA release, [11C]raclopride binding
THEORETICAL BACKGROUND 49
decreased in the ventral striatum in response to large monetary rewards compared with large
monetary losses (Pappata et al., 2002). [11C]raclopride binding has been shown to decrease in
the putamen and caudate in response to unpredictable compared with predictable rewards
(Zald et al., 2004) and in the ventral striatum (Martin-Soelch et al., 2011). In sum, these
results point to an involvement of the mesocorticolimbic and mesostriatal DA systems in the
processing of reward information. The following illustration provides an overview of reward
structures in the human brain.
Figure 6. Schematic illustration of dopamine projection pathways and circuitry regulating DA
release in the human brain. DA firing rates are maintained at tonic levels in part due to steady-
state inhibitory firing from the ventral pallidum. Excitatory projections from prefrontal cortex
project, amygdala and hippocampus synapse on striatal targets, including the nucleus
accumbens. The nucleus accumbens sends GABAergic projections to the ventral pallidum,
suppressing VP inhibition of VTA, thereby facilitating phasic burst-firing of VTA DA
neurons. Note: Placement of structure labels is approximate. Amyg = amygdala; Caud =
Caudate; DA = Dopamine; GABA = GABAergic projections; Glu = glutamatergic
projections; Hipp = hippocampus; NAcc = nucleus accumbens; Put = Putamen; SN =
Figure 6 Schematic illustration of dopamine projection pathways and circuitry regulating DA release in the human brain
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substantia nigra; VP = ventral pallidum; VTA = ventral tegmental area (adapted from
Treadway & Zald, 2011).
2.3.6 Findings supporting the role of DA in pain and reward
Recent findings suggest that pain and reward are mediated by similar neural pathways
in the CNS involving a complex network of subcortical and prefrontal structures related to
both  the  DA  and  the  opioid  systems  that  influence  each  other  on  a  neurobiological  and
motivational level (Borsook et al., 2007; Kut et al., 2011; Leknes & Tracey, 2008). In
addition, several findings showed that rewards, including pleasurable stimuli such as food,
music or odors, pleasurable activities and positive affective states have an analgesic effect and
decrease perceived pain intensity (Leknes & Tracey, 2008; Lewkowski, Young, Ghosh, &
Ditto, 2008; Roy, Piche, Chen, Peretz, & Rainville, 2009; Villemure & Bushnell, 2009).
Relief fits the definition of reward and can be as pleasurable as other reward types (Leknes &
Tracey, 2008). For instance, it has been shown that monetary gain and omission of monetary
loss activated overlapping regions in the ventromedial prefrontal cortex (Kim, Shimojo, &
O'Doherty, 2006; Ursu & Carter, 2005). Furthermore, activation in Nucleus accumbens has
been shown to correlate with relief pleasantness during an appetitive reward task (Leknes,
Lee, Berna, Andersson, & Tracey, 2011). In the context of pain and especially chronic pain,
relief from pain is rewarding. A psychophysical study confirmed the rewarding qualities of
pain relief (Leknes, Brooks, Wiech, & Tracey, 2008; Leknes et al., 2011). Neuroimaging
studies yielded evidence for involvement of similar brain regions in pain relief and reward.
For instance an involvement of the lateral prefrontal cortex has been shown in taste reward
(Kringelbach, de Araujo, & Rolls, 2004) and also in hyperalgesic pain (Lorenz, Minoshima,
& Casey, 2003). Further, fMRI and dopamine ligand PET studies showed involvement of the
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nucleus accumbens and the ventral striatum in monetary reward (Scott, Stohler, Egnatuk, et
al., 2007; Smith & Berridge, 2007) and drug reward (Drevets et al., 2001) and also in
expectation of pain (J. Jensen et al., 2003; Scott et al., 2006) and pain-induced analgesia
(Gear, Aley, & Levine, 1999). Additional anatomical substrates responsible for this mutual
influence of pain and reward include the anterior and posterior insula, amygdala, orbitofrontal
cortex, medial prefrontal cortex, anterior cingulate cortex (ACC), dorsal striatum, ventral
pallidum, thalamus, hypothalamus midbrain, amygdala, hippocampus cerebellum and
brainstem (for review see Leknes & Tracey, 2008).
2.3.7 Alterations of pain reward-interactions with chronic pain
Recent evidence suggests that pain, in particular long-term pain, impairs several
aspects of reward processing. First, chronic pain is associated with anhedonia, i.e. the inability
to feel pleasure (Marbach & Lund, 1981; Marbach, Richlin, & Lipton, 1983). Anhedonia has
been hypothesized to be related to hypofunction of the DA system, that could affect the neural
processing of rewarding information (Willner, 2000). Second, decreased reward sensitivity
and/or decreased motivation has been observed in rats with neuropathic pain (Ozaki et al.,
2002). Third, impaired operant learning of pain sensitization and habituation has been found
in FMS patients (Becker, Kleinbohl, Baus, & Holzl, 2011). Fourth, impaired decision making
based on reward and punishment has been reported in patients with chronic back pain and
complex regional pain syndrome (CPRS) (Apkarian et al., 2004). Taken together, these
findings suggest that pain-reward interactions are impaired by chronic pain. However, no
other study has examined the precise role of DA in this relation so far. The following section
contains the empirical work of this thesis.
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Abstract
Dopamine D2/D3 receptor availability at rest and its association with individual pain
perception was investigated using the [11C] raclopride PET-method in 24 female Fibromyalgia
(FMS) participants with (FMS+, N=11) and without (FMS-, N=13) comorbid depression and
in 17 healthy women. Thermal pain thresholds (TPT) and pain responses were assessed
outside the scanner. We compared the discriminative capacity, i.e. the individual’s capacity to
discriminate between lower and higher pain intensities and the response criterion, i.e. the
subject’s tendency to report pain during noxious stimulation due to psychological factors.
Ratios of striatal region/cerebellum tissue radioactivity concentrations (SCR) were calculated
as a measure of D2/3 receptor availability. The main findings were 1) no differences in striatal
D2/3 receptor availability between FMS+ and FMS- patients compared to healthy controls; 2)
a negative correlation between D2/3 receptor availability in the right caudate nucleus and TPT
in FMS+; 3) positive associations between TPT and D2/3 receptor availability in left
putamen, caudate and nucleus accumbens in healthy controls; 4) a positive association of the
response criterion with D2/3 receptor availability in the right nucleus accumbens in FMS-;
and 5) no correlations between D2/3 receptor availability and discriminative capacity in any
region or group. Our results suggest that the dopaminergic function is associated with pain
sensitivity in FMS patients in a different way than in healthy subjects, and that this
association is mediated by psychological aspects of pain rather than by the discriminative
capacity of the sensory system mediating pain.
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Introduction
Fibromyalgia syndrome (FMS) is an idiopathic, diffuse soft-tissue pain syndrome with
unclear pathophysiology (Bellato et al., 2012; Wolfe, 1990). Major depressive disorder
(MDD) is the most frequent psychiatric comorbidity in FMS (Fietta et al., 2007). A growing
awareness of the role of mesolimbic dopamine (DA) in pain perception, specifically in anti-
nociception, has emerged in recent years (Hagelberg et al., 2004; Jarcho et al., 2012; Leknes
& Tracey, 2008; Potvin, Grignon, & Marchand, 2009; Wood, 2008). Although its precise
function in nociceptive processes is only partially understood, DA regulation has been shown
to be disrupted in MDD and chronic pain (Epstein et al., 2006; Wood, 2008). Several Positron
Emission Tomography (PET)-  studies demonstrated altered post-synaptic striatal DA
neurotransmission in chronic neuropathic pain syndromes including burning mouth, and
atypical facial pain, (Hagelberg, Forssell, Aalto, et al., 2003; Hagelberg, Forssell, Rinne, et
al., 2003; Wood, Schweinhardt, et al., 2007) while an alteration of presynaptic DA
transmission was evidenced in FMS. However, postsynpatic DA function has not been
investigated so far in FMS and the role of depression in the DA changes observed in chronic
pain is not clear.
Moreover a positive correlation between individual pain sensitivity and striatal
baseline raclopride binding was observed in healthy volunteers (Hagelberg et al., 2002;
Pertovaara et al., 2004; Scott et al., 2006). Pain sensitivity can be determined using the Signal
Detection Theory (SDT) (Chapman, 1980; Clark, 1966), that distinguishes two measures: the
discriminative capacity, a measure of neurosensory sensitivity, reflecting the subject’s ability
to discriminate between two stimuli of similar, yet distinct, intensities. A low discriminative
capacity is associated with relative insensitivity to noxious stimulation and indicates an
attenuation of neural activity in the sensory system (Clark & Mehl, 1971). The response
criterion is independent from discriminability and locates the person’s overall tendency to
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report pain; a high value indicates a stoical attitude (Clark, 1974; Clark & Mehl, 1971). The
response  criterion  and  thermal  pain  threshold  (TPT)  were  shown  to  be  inversely  correlated
with the D2/D3 Binding Potential (BP) in the right putamen in healthy volunteers, whereas
the sensory discriminative capacity was not significantly correlated with the D2/D3 BP in any
striatal region (Pertovaara et al., 2004). The association between measures of pain sensitivity
with D2/D3 binding has not been yet examined in chronic pain conditions.
Here, we investigated the D2/D3 receptor availability at rest between FMS participants
with (FMS+) and without (FMS –) comorbid depression compared to healthy controls using
the [11C] raclopride PET method to measure postsynaptic striatal D2/D3 receptor availability.
We expected FMS patients to show reduced [11C] raclopride binding (measured as the ratio of
striatum to cerebellum binding, SCR) in striatal regions compared to healthy controls,
reflecting a decreased postsynaptic availability of D2/D3 receptors in these patients as already
described at the presynaptic levels (Wood, Patterson, et al., 2007) and in agreement with
findings for neuropathic pain conditions (Hagelberg, Forssell, Aalto, et al., 2003; Hagelberg,
Forssell, Rinne, et al., 2003). We expected the reduction to be more pronounced in FMS+
patients than FMS- patients. Additionally, we aimed to test the association between pain
sensitivity and striatal D2/D3 receptor binding with regard to the role of comorbid MDD. We
expected FMS patients to have decreased thermal pain thresholds (TPT) and thermal pain
tolerance (TOL), correlated to altered D2/D3 receptor availability, but for pain responses to
show  no  correlation  with  SCR  in  striatal  regions.  Together,  we  believe  that  such  evidence
would indicate that the dopaminergic influence on pain sensitivity is impaired in FMS.
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Material and Methods
Subjects
Given the predominance of women in FMS (Wolfe et al., 1995) and to reduce the
heterogeneity of study samples, we decided to only include women in this study. A total of 24
female FMS patients were compared to 17 age- and gender-matched healthy control subjects.
Among the FMS patients 11 subjects were diagnosed with comorbid MDD. All FMS+
patients had the onset of MDD subsequent to the FMS diagnosis. A description of clinical and
demographic data parameters for the FMS patients is provided in Table 1. FMS patients
fulfilling the American College of Rheumatology (ACR) classification criteria for
Fibromyalgia (Beck, Ward, Mendelson, Mock, & Erbaugh, 1961; Wolfe, Smythe, Yunus,
Bennett, Bombardier, Goldenberg, Tugwell, Campbell, et al., 1990) with decreased pressure
pain thresholds at a minimum of 11 of 18 specific tender points, located in 9 paired regions of
the  body,  were  recruited  from  the  Division  of  Rheumatology  at  the  University  Hospital
Zurich. They were recruited through flyers in medical practices, advertisements in
newspapers, and advertisements on websites associated with FMS. Controls were recruited
through flyers on bulletin boards in public places. Current and/or chronic medical conditions,
current and/or lifetime psychiatric diagnoses, acute or chronic pain and medication other than
oral contraceptives were exclusion criteria for the controls. All FMS patients had their FMS
diagnosis confirmed by an experienced rheumatologist (HS) through clinical examination,
including measurements of pain thresholds at tender points using a digital dolorimeter (LD
100 NRS, AC Engineering Basel, Switzerland). FMS subjects had a mean pain duration of
13.46 years (SD=11.98), and a mean number of 16 tender points (SD=3.66). FMS subjects
were allowed to continue their SSRI (selective serotonin-reuptake inhibitors), TCA (tricyclic
antidepressants) and NSAID (non-steroidal anti-inflammatory drugs) medication during the
study. A total number of 12 FMS patients were taking antidepressant medication either for
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pain or depressive symptoms. The use of opioids, neuroleptics, antiepileptics, and lithium was
an  exclusion  criterion.  All  subjects  were  tested  for  comorbid  psychiatric  disorders  using  the
SCID (Structured Clinical Interview for DSM-IV (First, 2002)). This instrument was also
used to diagnose MDD in the FMS group. The severity of depression was measured with the
Beck  Depression  Inventory  (BDI)  (Beck  et  al.,  1961),  German  version  (Hautzinger,  Bailer,
Worall, & Keller, 1995), and the Montgomery Åsberg Depression Scale (MADRS)
(Montgomery & Asberg, 1979). Anxiety was assessed using the State-Trait Anxiety Inventory
(STAI) (Laux, Glanzmann, Schaffner, & Spielberger, 1981). All participants were screened
for general MRI and PET exclusion criteria, pregnancy (pregnancy test on the day of
scanning), and breast-feeding. They were required to sign an informed consent which
explained the procedures of the study prior to information and testing. The study was
approved by the Ethical Committee of the Canton Zurich and the Swiss Federal Department
of Health (Bagatzounis, Willner, Oppitz, & Flentje) in accordance with the current version of
the declaration of Helsinki (Rickham, 1964) and the Swiss regulatory requirements.
PET image acquisition
[11C] raclopride is an established in vivo method for estimating the availability of
D2/D3 receptors in the brain. The D2/D3 receptor antagonist [11C] raclopride was produced
on site according to Good Manufacturing Practice (GMP) guidelines. PET scans were
acquired using a PET/CT scanner with an axial field of view of 15.3 cm in 3D mode
(Discovery STE, GE Healthcare, Waukesha, WI, USA) at the Department of Nuclear
Medicine at the University Hospital Zurich. PET data were reconstructed using filtered back
projection and segmented attenuation correction, for which a low dose CT scan was acquired.
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On the day of the PET study, subjects were asked to eat a well-balanced meal before the PET
scanning and not to consume too many liquids to ensure personal comfort during the scans.
The PET measurement took place in the same time frame (Monday afternoon from 3 pm to
5pm) for all participants. [11C] raclopride was injected as a slow bolus (260+/-20 MBq).
Dynamic scanning was initiated at the time of tracer injection and continued for 60 min (31
frames of 4x15sec, 8x30sec, 9x60sec, 2x180sec, 8x300sec, total 60 min duration). Image data
from 40-50 minutes were averaged and exported for further processing in the PMOD software
(Version 3.2, PMOD Technologies, Zurich, Switzerland).
Magnetic resonance imaging
Each subject received a high-resolution T1 weighted magnetic resonance scan (3D
fast-field  echo  scans  with  160  slices,  1mm isotropic  resolution,  TR= 18ms,  TE= 10ms,  flip
angle= 30°) for co-registration with PET images. All images were checked for structural
abnormalities and lesions by a clinical neuroradiologist.
Determination of thermal pain threshold (TPT), pain tolerance threshold (TOL), and
pain modulation
Standardized pain testing procedures were conducted by the same investigator on the
same day  as  the  PET scanning  with  each  subject  in  a  separate  session  in  a  quiet  room with
constant ambient temperature. Thermal pain threshold (TPT) and thermal pain tolerance
(TOL) were determined using a method of limits procedure (Hansen, Hopf, & Treede, 1996).
Thermal cutaneous pain response was measured by delivering heat stimuli to the thenar of the
non-dominant hand with a 27-mm-diameter thermal contact thermode (CHEPS, Medoc Ltd,
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Ramat Yishai, Israel). The CHEPS thermode has a heating rate of 70°C/s and a cooling rate of
40°C/s. The same heating and cooling rate was applied during the whole procedure. The
CHEPS thermode has a subject response device that immediately records the temperature
once activated, and resets the thermode to the adaptation temperature in preparation for the
next trial. The area of the stimulus surface was 5.7. cm2. TPT and TOL estimation was based
on five thermal stimuli starting at 32°C and rising linearly at a rate of 1°C/s until it was
stopped either by a button press or when the maximum temperature of 52°C was reached. To
determine TPT, subjects were asked to press the button on the response device when they
experienced pain for the first time. To examine TOL, subjects were asked to push the
response button when the sensation on their hand became intolerable or unbearable. The
experimental paradigm for the pain modulation was adapted and slightly modified from the
study of (Pertovaara et al., 2004). Heat stimulation started at 34.5°C and the temperature was
increased linearly at a rate of 3°C/s to one of the six predetermined temperatures (45.8, 46.3,
46.8, 47.3, 47.8, and 48.3°C) for a duration of 4s, after which the stimulus temperature
returned to baseline. The interval between successive stimulations was 15s. Each stimulus
temperature was applied eight times and the order the stimuli were presented was randomized
across  subjects.  After  presentation  of  each  stimulus,  the  subject  was  asked  to  rate  the
sensation evoked by the stimulus using a numerical rating scale ranging from 0 = no pain at
all to 10 = strongest pain imaginable. Before the actual testing sessions all subjects went
through a brief training session in which they were introduced to the experimental condition.
The area of stimulation was slightly varied by moving the thermode either to the left or right
side for each trial to prevent sensitization.
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Determination of the subject’s discriminative capacity and response criterion
We chose  the  same components  as  (Pertovaara  et  al.,  2004)  derived  from the  Signal
Detection Theory (SDT) to determine the individual response characteristics to pain.
Discriminative Capacity was computed by the trapezoidal rule as the area below the Receiver
Operating Characteristics (ROC) Curve which is generated by cumulating probabilities of hits
and false alarms for each response elicited by the stimulus temperatures of 46.8° vs. 47.3°
using PASW Statistics 21.0 (SPSS Inc., Chicago, Ill, USA). The exact description of the
calculations of the response criterion is provided in detail elsewhere (Pertovaara et al., 2004).
Briefly, the criterion was defined as the rating scale criterion where half the responses (to both
stimulus intensities in each pair) are divided into higher response categories and the other half
into lower response categories. The response criterion was defined as C=0.5(ZSN+ZN). Within
the calculation, the probability of rating a stimulus of 47.3° as painful (rating categories 6-10
pooled together) was converted to a Z score (ZSN) as described by Gescheider (1997, pp.122-
123 and Table A). The probability of rating a stimulus of 46.8° as non-painful (rating
categories 1-5 pooled together) was also converted to a Z score (ZN).
Data analysis
ROI analysis
All PET emission scans were reconstructed using 3D filtered back projection
including a 6mm FWHM Hanning filter, producing an estimated final FWHM (full width at
half maximum) of 10-12mm. Corrections for subject motion during the 60 min PET
acquisition were performed with a mutual information registration of each image frame to a
standard frame (0-8min after injection) before attenuation correction. Based on the calculated
motion, the transmission images were re-sliced and projected for final attenuation correction,
REPORT 1 61
reconstruction and realignment. The realigned frames were summed to generate an image that
was co-registered with the corresponding MRI image using PMOD software Version 3.2
(PMOD Technologies Ltd, Zurich, Switzerland). This was performed for the first 8 minutes of
scanning, during which the radiotracer distribution was most sensitive to cerebral blood flow
(CBF), and thus for the cortical outlines to be sufficiently evident in order to guide image co-
registration.  The  PET  frames  were  summed  and  co-registered  with  the  corresponding
magnetic resonance image, and both images were transformed linearly into standardized
stereotaxic space using the Montreal Neurological Institute template (Collins, Neelin, Peters,
& Evans, 1994). Mean tissue radioactivity concentrations were extracted using MRI based
regions of interest (ROI’s), defined on a template MRI image using PMOD software in the
anteroventral striatum, putamen, nucleus accumbens, caudate nucleus and cerebellum after
Drevets et al. (Drevets et al., 2001; Drevets et al., 1999). Each individual MRI was registered
to the template brain and the ROI’s were repositioned as needed to accommodate for
individual differences in anatomy. The anatomical accuracy and symmetry of each set of
individual ROI’s was verified by a neuroscientist familiar with striatal anatomy (CMS). These
ROI’s were then back-transformed into the subject’s native MRI space and applied to the co-
registered  PET  images  (example  in  Figure  1).  Ratios  of  striatal  region/cerebellum  tissue
radioactivity concentrations (SCR) were obtained. For each region, the ROI ratios for patients
and controls were compared with those for FMS+ and FMS- patients and controls and
correlated with pain thresholds and measurements.
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Figure 7:. ROI’s placement. Transverse view Cau: Nucleus caudatus; NA: Nucleus
accumbens; Pu: Putamen
Analysis of behavioral data
PASW Statistics 21.0 software (SPSS Inc., Chicago, Ill, USA) was used for statistical
analysis. Data distribution was tested with the Kolmogorov-Smirnov test and by observing
data histograms. The results of normally distributed data are presented as mean +/- standard
deviations. One way analysis of variance (ANOVA) was used to assess differences in D2/D3
receptor availability between groups (healthy, FMS-, FMS+) for each region of interest. The
difference between groups for experimental pain ratings (pain threshold, discriminative
capacity, and response criterion) of each group was tested using independent samples t-tests
and one-way ANOVA followed by post-hoc tests, where appropriate. P<0.05 was considered
to represent a statistically significant difference.
Associations between D2/D3 receptor availability and psychophysical results (pain
threshold, discriminative capacity, response criterion) were determined using Pearson’s
coefficient of correlation. P<0.05 was considered as statistically significant.
Figure 7 ROI’s placement
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Results
ROI Analyses
Mean  SCR  are  summarized  in  Table  2.  Analysis  of  postsynaptic  D2/D3  receptor
availability, measured by [11C] raclopride, demonstrated no significant group difference
between healthy subjects, FMS- and FMS+ patients in any of the striatal regions investigated
(see Table 2). Analysis of postsynaptic D2/D3 receptor availability for the collapsed FMS
group showed no group difference compared to healthy subjects.
Experimental pain ratings (thermal pain threshold (TPT), pain tolerance threshold
(TOL), response criterion, discriminative capacity)
Table 3 represents the mean values of all experimental pain ratings. An independent
samples t-test was conducted to compare TPT and TOL between all FMS patients (n=24) and
healthy controls (n=17). FMS patients showed a significantly lower TPT (m=41.1, SD=4.5)
compared to healthy subjects (m=45.0, SD=4.4) t(39)=2.8, p=0.01. Also the TOL was
significantly lower in FMS patients (m=44.7, SD=3.7) compared to healthy subjects (m=47.7,
SD=3.7) t(39)=2.5, p=0.02. The one-way ANOVA considering 3 groups of subjects showed
significant effects for TPT F(2,38)=4.34, p=0.02) and TOL F(2,38)=3.7, p=0.03). A post-hoc
Gabriel test indicated that the FMS+ patients had significantly lower TPT (p<0.02) and TOL
(p<0.03) than healthy subjects. The FMS- group did not significantly differ from the other
two groups. The index of response bias (response criterion) and the discriminative capacity
did not differ significantly between the three groups F (2.35)=0.61, p>0.94 (resp.
F(2.16)=1.18, p>0.33 for discriminative capacity). Response criterion was not correlated with
TPT (healthy subjects p>0.6, FMS- p>0.07 and FMS+ p>0.9) or TOL (healthy subjects p>0.3,
FMS- p>0.3, FMS+ p>0.09). Discriminative capacity was not associated with TPT (healthy
subjects p>0.3, FMS- p>0.4, FMS+ p>0.2 ) or TOL (healthy subjects p>0.4, FMS- p>0.7,
FMS+ p>0.2) in any of the groups.
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Correlation of D2/D3 receptor availability with pain responses
Thermal Pain Threshold (TPT)
In FMS+ patients, striatal D2/D3 receptor availability in the right nucleus caudate was
negatively correlated with TPT (r=- 0.65, p<0.03) (see Figure 8). For the FMS- patients,
however, no significant correlations with TPT could be determined (p>0.4) (see Figure 9).
In healthy subjects, striatal D2/D3 receptor availability in the left putamen (r=0.53, p<0.03),
left caudate nucleus (r=0.48, p<0.04), and left nucleus accumbens (r=0.5, p<0.01) was
positively associated with TPT (see Figure 10).
Thermal Pain Tolerance (TOL)
No significant correlations between striatal D2/D3 receptor availability and TOL were
found in any of the three groups (p>0.2).
Response criterion
In healthy subjects and FMS+ patients no significant correlations of the response
criterion with the D2/D3 receptor availability in any striatal region could be determined. In
contrast, the FMS- patients showed a significant correlation of the subject’s response criterion
with the D2/D3 receptor availability in the right nucleus accumbens (r=0.72, p<0.01) (see
Figure 11).
Discriminative capacity
The  index  of  the  subject’s  discriminative  capacity,  the  area  under  the  ROC  curve,
varied over a wide range between the subjects and did not differ between the three groups
F(1.38)=2.1, p=0.15. Correlations of the discriminative capacity with the D2 receptor
availability were not significant (p>0.17) in any of the three groups.
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Discussion
The major innovation of the present study was that it examined the link between
striatal D2/D3 receptor availability and individual pain perception in patients with
Fibromyalgia, both with and without comorbid MDD, compared to healthy subjects using the
[11C] raclopride PET method. To our knowledge, this is the first study investigating the link
between striatal D2/D3 receptor availability and individual pain responses in Fibromyalgia
that differentiated between individuals with and without depression.
Our main findings were (1) no differences in striatal D2/D3 receptor availability
between FMS patients with depression and without depression compared to healthy subjects,
(2) a positive association of the response criterion with D2/D3 receptor availability in the
right nucleus accumbens in FMS without depression, (3) a negative correlation between
striatal D2/D3 receptor availability in the right caudate nucleus and thermal pain threshold in
FMS patients with depression, (4) a positive association of D2/D3 receptor availability in the
left putamen, left caudate and left nucleus accumbens with thermal pain threshold in healthy
controls,  and  (5)  no  correlations  between  D2/D3  receptor  availability  and  discriminative
capacity in any of the groups, and regions. Unexpectedly, we did not find any differences in
D2/D3 receptor availability at rest across groups. This was also confirmed by a voxel-based
(statistical parametric mapping, results not shown) analysis which was performed post-hoc to
the ROI analysis and did not find any clear statistical effects. Our findings are at odds with
previous studies which have demonstrated reduced presynaptic DA activity in FMS (Wood,
Patterson, et al., 2007). There are several possible explanations for this. It is possible that
these previous findings were influenced by methodological differences, i.e. pre-synaptic
versus post-synaptic measures could explain these contradictory results. Furthermore, the
reductions in 6-18F fluoro-L-DOPA uptake were limited to mesencephalon including ventral
tegmental area and substantia nigra, suggesting that presynaptic neuronal integrity in the
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mesencephalon is a more sensitive indicator of fibromyalgia than postsynaptic receptor sites.
Moreover, these previous studies included smaller samples of patients and did not control for
depression or other comorbid disorders. Additionally, lower raclopride BP in FMS patients
than healthy controls in all functional sub-regions of the striatum during non-painful saline
infusion have been reported (Wood, Schweinhardt, et al., 2007). However it is not entirely
clear if this result reflects decreased DA receptor density or a greater release of DA in
response to non-painful saline infusion and is therefore not directly comparable to our
experimental paradigm. No study so far has investigated the baseline DA changes at the post-
synaptic level in Fibromyalgia (i.e. in the absence of noxious stimuli).  A recent study
suggested the role of DA in modulating the salience of a pain stimulus rather than providing
evidence for direct anti-nociceptive effects (Becker et al., 2013). Although dopaminergic
mechanisms may differ in acute versus chronic pain, this proposed role of DA in mediating
the motivational value of a pain stimulus may account for the associations unexpectedly found
in our FMS groups and the absence of a difference in D2/D3 receptor availability at post-
synaptic level. However, this is very speculative and should be investigated in future studies.
The Sensory Detection Theory analysis showed that Fibromyalgia patients with and
without depression did not set a higher criterion for reporting pain and did also not differ in
terms  of  discriminative  capacity  from  our  healthy  controls.  In  addition,  the  thermal  pain
tolerance and thresholds of Fibromyalgia patients with depression differed from healthy
controls but did not correlate with the response criterion or discriminative capacity. The
results from the correlation analysis between D2/D3 receptor availability and psychophysical
results in Fibromyalgia patients with and without depression are unexpected. Our results
suggest a potential link between D2/D3 receptor availability and pain perception due to
psychological factors in FMS which differ however between patients with and without
comorbid depression. In Fibromyalgia patients without depression, D2/D3 receptor
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availability in the right nucleus accumbens was positively associated with the criterion to
report pain, but not with the index for discriminative capacity, thermal pain threshold or
tolerance. Since the response criterion is a measure for psychological aspects of pain, the pain
sensitivity in Fibromyalgia patients without depression appears to be determined mainly by a
dopaminergic influence on psychological factors that in turn influence the subject’s tendency
to report pain rather than by physiological factors. In line with this finding psychological
factors have been shown to have an important role in variability of pain ratings between
subjects (Clark, 1974; Clark & Mehl, 1971). On the other hand cognitive and affective
variables frequently occurring in FMS such as depression, anxiety or pain-related anxiety
(Lachaine, Beauchemin, & Landry, 2010; Rutledge, Mouttapa, & Wood, 2009) were related
to increased pain report and responses (Gil, Phillips, Edens, Martin, & Abrams, 1994). Also
personality traits associated with FMS (Malin & Littlejohn, 2012) such as detachment,
anxiety, and novelty seeking, were related to D2/D3 receptor availability (Breier et al., 1998;
Farde, Gustavsson, & Jonsson, 1997; Suhara et al., 2001) and increased pain report (Farde et
al., 1997). This matches the assumption that emotional and psychological processes may play
a particularly important role in promoting pain in these patients (Geisser et al., 2003; Staud,
2004) and that affect may contribute to pain in FMS (Staud, Price, Robinson, & Vierck, 2004;
Staud et al., 2003). In addition, D2 receptor-mediated neurotransmission in the ventral system
involving the nucleus accumbens, has been shown to be associated with emotional processing
of pain (Scott et al., 2006). Consistent with the possibility that psychological factors
contribute to pain in FMS via DA transmission, it has recently been proposed that DA could
play a role in modulating the salience of a pain stimulus (Becker et al., 2013), fostering
coping responses, rather than having direct anti-nociceptive effects. This mediating role of
DA might eventually explain why we found associations between striatal D2/D3 receptor
availability in regions associated with emotional modulation of pain and psychophysical
measures of emotional/attitudinal aspects of pain in our FMS patients. In Fibromyalgia
68 REPORT 1
patients with depression, D2/D3 receptor availability in the right caudate was negatively
associated with thermal pain threshold, but not with the response criterion or discriminative
capacity. Evidence showing that D2 receptor-mediated neurotransmission in the dorsal
caudate and putamen is associated with subjective ratings of sensory and affective qualities of
pain (Scott et al., 2006), suggests that D2/D3 receptor availability in the right caudate of
Fibromyalgia patients with depression influences non-sensory mechanisms underlying the
pain response rather than actual pain sensitivity. These results are in line with a previous
fMRI study which suggested that the presence of depression had no effect on the sensory-
discriminative processing of pain stimulation but had a selective effect on brain regions that
process the affective-motivational dimension of pain (Giesecke et al., 2005). Furthermore, this
result and the fact that FMS patients with depression conveyed a lower pain threshold than the
other subject groups, support the idea of a more pronounced deficit in pain inhibition in FMS
with comorbid depressive symptoms (de Souza, Potvin, Goffaux, Charest, & Marchand,
2009), suggesting that depression could influence pain perception in FMS via DA. Our
findings in Fibromyalgia patients with and without depression are not consistent with
previous reports in healthy subjects where the pain threshold and the response criterion were
inversely correlated with the D2/D3 BP in the human striatum (right putamen) (Pertovaara et
al., 2004). The same study showed that the discriminative capacity is not a critical factor
responsible for the association of pain responses with D2/D3 BP in healthy subjects
(Pertovaara et al., 2004). This result is in line with our findings both in healthy subjects and
Fibromyalgia patients. In accordance with our hypothesis, we found significant positive
correlations between the thermal pain threshold and D2/D3 receptor availability in striatal
regions including the left putamen, left caudate nucleus and the left nucleus accumbens in
healthy subjects. This result however, contradicts previous findings that reported direct
correlations between striatal D2/D3 receptors and pain thresholds in the right putamen
(Martikainen et al., 2005) (Hagelberg et al., 2002; Pertovaara et al., 2004; Scott et al., 2006).
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Lateralization differences in the DA system are well documented and an influence of gender
on lateralization of the function of the DA system has previously been shown (Martin-Soelch
et al., 2011). The deviation from the previous finding could therefore be explained by the
inclusion of women in our study while the other studies included only men (Pertovaara et al.,
2004). Furthermore, some pain-related phenomena such as pain threshold have been shown to
occur  with  a  laterality  bias  (Bar  et  al.,  2005;  Bar,  Greiner,  Letsch,  Kobele,  &  Sauer,  2003;
Leite-Almeida et al., 2012; Lugo, Isturiz, Lara, Garcia, & Eblen-Zaijur, 2002; Meh &
Denislic, 1994). Moreover, associations between the D2 binding capacity and conditioned
pain modulation, which reflects the capacity of the brain to inhibit and to modulate incoming
pain signals, have been reported in the left putamen (Hagelberg et al., 2002).
Several previous PET studies also using [11C] raclopride showed increased D2
receptor availability in chronic neuropathic pain conditions such as burning mouth syndrome
(Jaaskelainen et al., 2001) or atypical facial pain (Hagelberg, Forssell, Aalto, et al., 2003). An
overlapping pathophysiology between FMS and neuropathic pain has been suggested due to
shared clinical features such as paresthesias, hyperalgesia and allodynia (Maletic & Raison,
2009; Martinez-Lavin, Lopez, Medina, & Nava, 2003), but our results indicate that striatal
D2/D3 receptor availability in FMS patients with and without depressive symptoms are not
impaired in the same way as in chronic neuropathic pain conditions.
Abnormal sensorial thresholds were also evidenced in neuropathic pain such as
burning mouth syndrome or trigeminal non-idiopathic neuropathic pain (de Siqueira, Teixeira,
& de Siqueira, 2013). Abnormal sensory findings are considered important features in the
classification of neuropathic pain according to the International Association for the study of
pain (IASP) (T. S. Jensen et al., 2011). Therefore, the observation of abnormal sensorial
thresholds and the disrupted modulatory role of striatal D2/D3 receptors in pain processing in
FMS could be added to other neuronal changes observed in these patients (for instance
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impaired small fiber function in FMS) (Uceyler et al., 2013), contradicting the opinion that
FMS is a pure somatization disorder without demonstrable abnormality.
Some limitations merit attention. This study did not allow for differentiation between
D2/D3 receptor density or intrasynaptic dopamine concentration and the interpretation of
underlying neuronal factors should be treated with caution. Prior work indicates that [11C]
raclopride values from the bolus method are almost identical to binding values generated by a
bolus-infusion method (Carson, 2000; Watabe et al., 2000), in which DA release can be
indirectly measured for the same subjects. Although SPM analysis of PET ligand studies is a
viable alternative to ROI analysis,  especially for the exploration of changes without a priori
region definitions, requirements of the analysis include transformation of the PET data to
standard anatomical space, smoothing of the data and quantitative normalization to account
for global effects. In a small cohort as in our study, these processes may reduce the sensitivity
to subtle changes in raclopride binding. Standardization of the basal ganglia anatomy for SPM
analysis is a known challenge (in comparison to cortical anatomy). Therefore, our individual
anatomy MR-based VOI analysis may be considered to better account for individual basal
ganglia anatomy and improve the sensitivity of our PET measurements. Another limitation is
that we did not include chronic neuropathic pain patients to control for similarities or
differences between FMS and neuropathic pain. Further, we did not control for phases of
menstrual cycle in our participants. However, the majority of the participants were
postmenopausal (N=19, see Table 1). Finally, DA receptor binding results as well as the
individual responses to pain may have been biased by the patients’ medication, which
possibly influenced the testing procedures, including slower reaction times and anti-
nociceptive effects of antidepressants (N=12). Nevertheless, we found significant differences
between FMS patients and healthy subjects with regard to the estimation of pain thresholds,
and a previous study (Klauenberg et al., 2008) found no significant group difference
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concerning SSRI medication regarding all pain thresholds. It is however possible that the lack
of differences in D2/D3 receptor availability may be related to the medication.
Conclusion
To our knowledge, this is the first report on the association between D2/D3 receptor
availability and pain perception in FMS, distinguishing between FMS patients with and
without comorbid depression. Additionally, in comparison to previous studies in this field,
our study included a relatively large sample of patients. In conclusion, our data suggest that
there are no differences in D2/D3 receptor availability at rest between FMS patients with
depression and without depression compared to healthy subjects. This study presents novel
results suggesting that the association between D2/D3 receptor availability and pain
perception differs between healthy subjects and patients with Fibromyalgia. Furthermore, this
association also differed between FMS patients with and without depression, suggesting that
depression could influence pain perception in FMS. Our results suggest that alterations in the
dopaminergic system appear to be linked to pain sensitivity in FMS patients. Striatal D2/D3
receptor availability in Fibromyalgia patients with and without depression is associated with
psychological  aspects  of  pain  rather  than  the  discriminative  capacity  of  the  sensory  system
mediating pain. However, the exact mechanisms have yet to be elucidated and similarities
with chronic neuropathic pain patients with regard to the modulatory function of DA in pain
should be further explored. These findings contribute to the understanding of the function of
the dopaminergic system in central pain processing in healthy individuals and in patients with
FMS.
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Appendix
Table 2. Demographic and clinical characteristics of subjects with Fibromyalgia (FMS
without MDD N=13), (FMS with MDD N=11) and healthy controls (N=17)
Tabelle 2 Demographic and clinical characteristics of subjects with Fibromyalgia
FMS without
MDD
FMS with
MDD
Healthy
controls
F p
Variable Mean SD Mean SD Mean SD
Age 55.2 10.6 44.5 10.1 42.8 13.8 2.4 0.06
Education(years) 12.9 0.8 13.3 0.9 13.7 0.8 0.2 0.79
Duration FMS
(years)
13.9 11.9 12.9 10.9 0.9
Tenderpoints 17 3.5 14.5 3.5 0.2
Duration MDD
(years)
11.3 11.5
BDI 7.9 3.9 17.3 8.6 1.4 1.8 28.9 0.001*1
SHAPS 0.7 0.5 2.1 0.5 0 0.4 0.8 0.015*2
MADRS 5.9 1.5 15.5 9.4 0.3 0.7 30.5 0.001*1
PDI 18.7 10.6 25 6.7 3.1 7.7 18.1 0.001*1
Menopause 11 7 10
Medication
Antidepressants
4 9 0
Notes. BDI = Beck Depression Inventory; SHAPS = Snaith Hamilton Pleasure Scale; MADRS =Montgomery
Asberg Depression Scale; PDI= Pain disability index
ANOVA, level of significance two-tailed p<0.05
1 healthy<FMS without MDD<FMS with MDD
2 healthy<FMS with MDD
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Table 3. Mean regional [11C] raclopride striatal region/cerebellum ratios (SCR) for subjects
with Fibromyalgia (FMS without MDD N=13), (FMS with MDD N=11) and healthy controls
(N=17)
Tabelle 3 Mean regional [11C] raclopride striatal region/cerebellum ratios (SCR)
FMS without
MDD
FMS with MDD healthy controls
Region Mean SD Mean SD Mean  SD F p
Putamen1 5.2 0.5 5.2 0.6 5.2 0.7 0.005 0.9
Putamen2 4.9 0.8 5.1 0.4 5.1 0.8 0.49 0.6
ventral
Striatum1
4.1 0.8 3.7 0.8 3.5 0.9 2.01 0.1
ventral
Striatum2
4.1 0.8 3.8 0.8 3.6 0.9 1.07 0.4
Caudate
nucleus1
3.2 0.8 3.6 0.8 3.7 0.7 1.72 0.2
Caudate
nucleus2
3.9 0.4 4.1 0.5 3.9 0.7 0.32 0.7
nucleus
accumbens1
2.9 0.6 3.2 0.4 3.3 0.8 1.0 0.4
nucleus
accumbens2
3.6 0.9 3.2 0.4 3.7 0.7 1.65 0.2
Notes. *ANOVA, level of significance two-tailed p<0.05
1 left
2 right
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Table 4. Means of thermal pain threshold, thermal pain tolerance and thermal Sensory
Decision Indices (response criterion, discriminative capacity) for subjects with Fibromyalgia
(FMS without MDD N=13), (FMS with MDD N=11) and healthy controls (N=17)
Tabelle 4 Means of thermal pain threshold, thermal pain tolerance and thermal Sensory Decision Indices (response
criterion, discriminative capacity)
FMS without
MDD
FMS with MDD healthy controls F P
Variable Mean SD Mean SD Mean SD
Thermal pain
threshold
41.9 5.1 40.1 3.65 45.01 4.4 1.5 0.02*1
(TPT)
[C°]
Thermal pain
tolerance
45.5 3.4 43.9 4 47.7 3.7 1.65 0.03*1
(TOL)
[C°]
Response
criterion
1.04 1.1 0.98 1.12 1.13 1.1 0.06 0.9
Discriminative
capacity
0.51 0.13 0.59 0.12 0.57 0.15 1.05 0.35
Notes. *ANOVA, level of significance two-tailed p<0.05
1post-hoc test Gabriel: FMS with MDD<healthy controls
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Figure 8 Association of striatal D2 receptor availability in the right caudate nucleus with thermal pain threshold
in FMS patients with co-morbid MDD
Figure 8. Association of striatal D2 receptor availability in the right nucleus caudate with
thermal pain threshold in FMS patients with co-morbid MDD
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Figure 9. Lacking association of striatal D2 receptor availability and pain threshold in any
striatal region of interest in FMS patients without co-morbid MDD (here displayed:
striatal D2 receptor availability in right nucleus caudate)
Figure 9 Lacking association of striatal D2 receptor availability and pain threshold in any
striatal region of interest in FMS patients without co-morbid MDD
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Figure 10. Association of striatal D2 receptor availability in the left putamen PUL, left
caudate nucleus CNL, left nucleus accumbens NAC with thermal pain threshold in healthy
controls
Figure 10 Association of striatal D2 receptor availability in the left putamen, left caudate nucleus, and left nucleus
accumbens with thermal pain threshold in healthy controls
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Figure 11. Association of striatal D2 receptor availability in the right nucleus accumbens with
response criterion in FMS patients without co-morbid MDD
Figure 11 Association of striatal D2 receptor availability in the right nucleus accumbens with
response criterion in FMS patients without co-morbid MDD
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Abstract
Mesolimbic dopamine (DA) has been shown to be involved in the processing of pain and
reward. Fibromyalgia syndrome (FMS), characterized by chronic widespread pain, is
frequently associated with depression. Reduced DA function and reduced responses to reward
were also evidenced in depression. First evidence suggests that chronic pain might impair
reward processing. Therefore, reduced DA reaction to reward could be involved in depressive
symptoms and pain symptoms observed in FMS. We tested here whether striatal DA
responses to monetary rewards would be impaired in FMS patients compared to healthy
controls and whether this reduction would be stronger in FMS patients with co-morbid
depression (MDD). In 24 female FMS patients (11 with MDD) and 17 healthy controls,
differences in regional D2/3 receptor binding potential (ǻBP) between an unpredictable
reward condition and a sensorimotor control condition were measured using the bolus-plus-
constant-infusion [11C] raclopride method. The ǻBP was assessed in MRI-based striatal
regions-of-interest and compared between FMS patients with and without MDD and healthy
controls.
We found significant reductions in binding potential (BPND), presumably reflecting increased
dopamine release, in the reward vs. the control condition in the right nucleus accumbens and
right caudate nucleus. This reduction in the right nucleus accumbens was more prominent in
FMS patients with co-morbid MDD compared to healthy controls. Among FMS patients, this
reduction in the right caudate nucleus was significantly more prominent in those with co-
morbid MDD relative to those without MDD. The collapsed FMS group had a significantly
greater ǻBP than healthy controls in the right nucleus accumbens. This study showed that
FMS patients had an increased reaction to rewards that was more accentuated in patients with
MDD, suggesting that FMS patients exhibit dysfunctional DA responses to monetary rewards
relative to healthy controls.
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Introduction
Numerous neuroimaging studies show that pain and reward are mediated by similar neural
pathways in the central nervous system (for review see (Becker et al., 2012)) involving a
complex network of subcortical and prefrontal structures which are both related to the
dopamine (DA) and opioid systems (Borsook et al., 2007; Kut et al., 2011; Leknes & Tracey,
2008). It is well documented that the mesolimbic DA system is involved in reward processing
(Haber & Knutson, 2010; Hudson, Arnold, Keck, Auchenbach, & Pope, 2004). Several
studies demonstrated that rewards, including pleasurable stimuli or activities and positive
affective states, have an analgesic effect (Lewkowski et al., 2008; Roy et al., 2009; Villemure
& Bushnell, 2009). Chronic pain seems to alter brain systems that process pain and reward,
possibly affecting the pain-reward interactions (Becker et al., 2012). These findings maintain
a mutual influence of rewarding and painful stimuli that could be mediated through the DA
system. There is a high rate of co-morbidity between chronic pain and depression (Fishbain,
Cutler, Rosomoff, & Rosomoff, 1997; Wilson, Eriksson, D'Eon, Mikail, & Emery, 2002); the
prevalence of depression in chronic pain exceeds 20% (Fishbain et al., 1997; Wilson et al.,
2002) and often includes anhedonia, i.e., the reduced ability to enjoy pleasurable activities
(Marbach  &  Lund,  1981),  which  has  been  shown  to  be  related  to  a  dysfunction  of  the
mesolimbic DA system (Sarchiapone et al., 2006). Additionally there is a large body of
evidence  showing  that  the  DA  system  is  impaired  in  major  depressive  disorder  (MDD)
(Martin-Soelch, 2009). Disrupted physiological, behavioral and subjective aspects of reward
function are postulated to be critical to the development and pathophysiology of depression
(Forbes & Dahl, 2012; Hasler, Drevets, Manji, & Charney, 2004). However, the precise
mechanisms of the mutual pain-reward interaction are still not fully understood and only a
few studies investigated the influence of pain on reward respectively of rewards on pain in
humans (Leknes & Tracey, 2008), (Becker et al., 2012).
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A dysfunction of DA has been evidenced in chronic pain patients including higher DA D2
receptor availability in neuropathic pain and reduced presynaptic DA function in
Fibromyalgia (FMS) (Hagelberg, Forssell, Aalto, et al., 2003; Hagelberg et al., 2004; Wood,
Patterson, et al., 2007). FMS is an idiopathic, diffuse soft-tissue pain syndrome characterized
by lowered pain thresholds in the area of tendons and other pain-related symptoms such as
fatigue, sleep disruption, cognitive impairment and gastrointestinal symptoms (Wolfe, 1990).
Major depressive disorder (MDD) is the most frequent co-morbidity in FMS (Fietta et al.,
2007). Despite its high clinical significance, the neural correlates and the interaction between
psychological and neurobiological processes in the pathophysiology of FMS are still poorly
understood. Finally the influence of chronic pain symptoms as experienced in FMS on the
ability to enjoy reward has not been investigated yet.
We tested here the endogenous DA release associated with unpredictable monetary rewards
during bolus-plus-infusion [11C] raclopride PET scanning using a validated reward task
(Caine & Koob, 1994) in FMS patients without co-morbid MDD (FMS-), with co-morbid
MDD (FMS+) and healthy controls to investigate if FMS is associated with dysfunction of the
central reward system. We postulated that the healthy controls would evidence an increase of
striatal DA transmission in response to unpredictable reward and that this increase would be
reduced in FMS patients. Furthermore, we expected FMS+ patients to show a stronger
reduction of this effect than FMS- patients. Additionally, we hypothesized that depression,
anhedonia and pain disability scores would correlate negatively with DA release in response
to rewarding stimuli.
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Material and Methods
Research subjects
A description of clinical and demographic data parameters for the FMS patients is
summarized in Table 1. A total of 24 FMS patients fulfilling the American College of
Rheumatology (ACR) classification criteria for Fibromyalgia (Beck et al., 1961; Wolfe,
Smythe, Yunus, Bennett, Bombardier, Goldenberg, Tugwell, Campbell, et al., 1990) and 17
age- and gender-matched medically and psychiatrically healthy controls were included in the
study. Among the FMS patients 11 subjects met the DSM-V criteria (American Psychiatric
Association, 2013(APA)) for MDD (current and lifetime depressive episode). All subjects
were tested for comorbid psychiatric disorders using the SCID (Structured Clinical Interview
for DSM-IV; (First, 2002)). This instrument was also used to diagnose MDD in the FMS
group. All FMS+ patients had the onset of MDD subsequent to the FMS diagnosis. All FMS
patients had their FMS diagnosis confirmed by an experienced rheumatologist (HS) through
clinical examination, including measurements of pain thresholds at tender points using a
digital dolorimeter (LD 100 NRS, AC Engineering Basel, Switzerland). A description of
clinical and demographic data parameters for the FMS patients is provided in Table 1.
Exclusion criteria were current and/or chronic medical conditions, current and/or lifetime
psychiatric diagnoses, general MRI and PET exclusion criteria, pregnancy (pregnancy test on
the day of scanning), breast-feeding and medication other than oral contraceptives for FMS
patients and the controls. In addition, controls were excluded if they had diagnoses of acute or
chronic pain. FMS subjects were allowed to continue their SSRI (selective serotonin reuptake
inhibitors), TCA (tricyclic antidepressants) and NSAID (non-steroidal anti-inflammatory
drugs) medication during the study. A total number of 12 FMS patients were taking
antidepressant medication either for pain or depressive symptoms. The use of opioids,
neuroleptics, antiepileptics and lithium was an exclusion criterion.
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All participants were required to sign an informed consent which explained the procedures of
the study prior to information and testing. The study was approved by the Ethical Committee
of  the  Canton  Zurich  and  the  Swiss  Federal  Department  of  Health  (Bagatzounis  et  al.)  in
accordance  with  the  current  version  of  the  declaration  of  Helsinki  (Rickham,  1964)  and  the
Swiss regulatory’s requirements.
Experimental conditions
To  measure  the  endogenous  DA  release  to  unpredictable  rewards  we  used  a  slot-
machine task adapted from Martin-Soelch et al. (Martin-Soelch et al., 2011) (see Figure 1)
that  involved  two  conditions,  a  sensorimotor  task  followed  by  a  reward  condition,  each
consisting of 180 trials, each of an average duration of 8s. In the monetary-reward condition
subjects received financial reward unpredictably, in a pseudo-randomized order with an
average  of  one  reward  per  four  trials.  In  the  sensorimotor  control  condition  subjects
performed the same task without receiving rewards. The sensorimotor condition served as
control  for  motor  activation  and  other  nonspecific  aspects  of  task  performance.  Before
scanning, subjects performed a short practice session of each task. During scanning subjects
rested for the initial 20 min to allow [11C] raclopride to approach equilibrium. The ability of
this design to induce equilibrium and task-related changes in raclopride binding was tested by
Martin-Soelch et al. (Martin-Soelch et al., 2011) and confirmed by Savitz et al. (Savitz et al.,
2013) During the subsequent 24+/-2min subjects performed the sensorimotor control task.
Beginning  50min  after  the  start  of  the  [11C] raclopride infusion, subjects performed the
monetary reward condition for 24.1+/-1.7min. This timing allowed the distribution of [11C]
raclopride to reach equilibrium for each of the two task conditions during the scanning epochs
described below. During the 24min epochs that corresponded to each task condition, subjects
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alternated between 2-min periods in which they actively performed the task and 1-min periods
when they rested to minimize fatigue. Each subject won a total of 54 SFr. (62 USD) during
the rewarded condition, which they received in cash following the study.
Behavioral assessments
During the slot machine task (once in each condition only) participants rated their
currently perceived pain intensity using a horizontally oriented visual analog scale (VAS),
ranging from 0 (no pain at all) to 5 (most intense pain imaginable). Before beginning image
acquisition, participants were familiarized with the rating scales to ensure that they used the
scales appropriately. All pain ratings during the behavioural task are shown in Table 4.
PET image acquisition
The D2/D3 receptor antagonist [11C] raclopride was produced on site according to
Good Manufacturing Practice (GMP) guidelines. The PET examinations were performed on a
full ring PET/CT scanner with an axial field of view of 15.3 cm in 3D mode (Discovery
DSTX, GE Healthcare, Waukesha, WI, USA) at the Department of Nuclear Medicine at the
University Hospital Zurich, Switzerland. The emission data was corrected for attenuation,
scatter, randoms, and dead time using the corresponding CT (120 kV/80 mA), and
reconstructed using a standard iterative algorithm (ordered set expectation maximization
[OSEM]). The [11C] raclopride (415+/-30 MBq) was administered as an initial bolus over 60s
after  Watabe  et  al.  (Watabe  et  al.,  2000),  followed  by  a  maintenance  infusion  over  the
remainder of the scanning session (a total of 90 min) using a computer-operated pump
(Arcomed, syramed µSP600, Regensdorf, Switzerland). Dynamic emission scanning (41
frames of 0 to 6000 seconds (i.e. 100 min scan), framed as 4 x15, 8 x 30, 9 x 60, 2 x 180, 4 x
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300, 6 x 200, 8 x 300 sec) was initiated with injection of the [11C] raclopride bolus. BPND in a
resting state was measured in all participants one week before the B/I [11C] raclopride PET
scan and the results are described in Ledermann et al. under review.
Magnetic resonance imaging
Each subject received a high-resolution T1 weighted magnetic resonance scan (3D
fast-field  echo  scans  with  160  slices,  1mm isotropic  resolution,  TR= 18ms,  TE= 10ms,  flip
angle  =  30°)  on  a  3  tesla  Philips  Achieva  scanner  (Philips  Medical  Systems)  for  co-
registration  with  PET  images.  All  images  were  checked  for  structural  abnormalities  and
lesions by a clinical neuroradiologist.
PET imaging data analysis
ROI analysis
PMOD software Version 3.2 (PMOD Technologies Ltd, Zurich, Switzerland) was
used for PET data analysis. As an initial step, we corrected for possible head motion-induced
artifacts during the 100 min. PET acquisition were performed with a mutual information
registration of each image frame to a standard frame (10-15 min after injection) before
attenuation correction. Based on the calculated motion, the transmission images were resliced
and projected for final attenuation correction, reconstruction and realignment. The realigned
frames acquired during the first 8 min of scanning, during which the radiotracer distribution
was  most  sensitive  to  cerebral  blood  flow  (CBF)  so  that  cortical  outlines  were  sufficiently
evident to guide image co-registration, were summed to generate an image that was co-
registered to the corresponding MRI image using PMOD software. The delivered
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transformation matrix was applied to the composite images consisting of (i) baseline (frames
acquired between 40 and 50 min) and (ii) the reward condition images (frames acquired
between 60 and 80 min), which were acquired under equilibrium conditions achieved as
subjects performed the sensorimotor control and monetary reward tasks (Fig. 1), respectively,
after Martin-Soelch et al. (Martin-Soelch et al., 2011). Using a region-of-interest (Abulencia
et al.) approach, mean tissue radioactivity concentrations from baseline and reward images
were extracted using MRI-based regions of interest (ROIs), defined on a template MRI image
using PMOD software (PMOD Technologies Ltd, Zurich, Switzerland) in the anteroventral
striatum, ventral putamen, dorsal putamen, middle caudate, dorsal caudate, nucleus
accumbens and cerebellum (Fig. 2), after Drevets et al. (Drevets et  al.,  2001; Drevets et  al.,
1999). Each individual MRI was registered to the template brain and the ROI’s were
repositioned as needed to accommodate for individual differences in anatomy. The anatomical
accuracy and symmetry of each set of individual ROI’s was verified by a neuroscientist
familiar with striatal anatomy (C.M.S). These ROI’s were then back-transformed into the
subject’s native MRI space and applied to the co-registered PET images. Mean radioactivity
in the reference region (cerebellum; C’) was used to control for the effects of free and non-
specifically bound [11C] raclopride. The [11C] raclopride binding potential (BPND), which is
inversely correlated to endogenous DA release, was chosen as the measurement of D2
receptor binding for each brain region.
Decay-corrected tissue radioactivity concentrations were obtained from each ROI using a
calibrated phantom standard to convert tomographic counts to becquerels per millilitre. C’,
the mean radioactivity in the reference region (cerebellum) was used to factor out the effects
of free and non-specifically bound [11C] raclopride. The percentage change in [11C] raclopride
binding was computed as the difference in BPND(non-displaceable) between baseline and reward
images after Watabe et al. (Watabe et al., 2000) using the following equation forǻBP.
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(Creward – C’reward)  _  (Cbaseline – C’baseline)
          C’reward                   C’baseline
ǻBP =        ____________________________________             x  100
      (C baseline – C’ baseline)
             C’ baseline
The obtained negative values of [11C] raclopride ǻBP indicated the percentage of
displacement of [11C] raclopride by endogenously released DA, with the greater negative
values corresponding to greater [11C] displacement.
To test the significance of ǻBP in each region and each group, we used one sample t-tests.
The a priori hypothesis was tested using one-factorial ANOVA with group as factor on the
ǻBP obtained  in  striatal  regions  of  interest,  with  a  null  hypothesis  that  there  is  no  effect  of
group. Between-group comparisons of ǻBP for the collapsed FMS group were conducted
using one-way ANOVA. A repeated measure ANOVA with factors region and laterality and
group as between subject factor was performed to assess differential responses between
regions. Additional analyses explored correlations between depression (BDI, MADRS),
anhedonia (SHAPS), anxiety (STAI) and pain disability (PDI) scores and ¨BP. To assess the
difference in pain ratings between sensorimotor control and reward condition repeated
ANOVA’s with between-subject-factor group were performed.
Results
The participants’ demographic and clinical data are summarized in Table 1. There
were no significant differences in mean age and education between the FMS patient groups
and the healthy controls. Tender point evaluation and duration of illness were similar across
FMS groups. Measures for pain, depression, anhedonia and anxiety were typically elevated in
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the FMS patients groups, but depression and pain ratings were significantly greater in FMS+
compared to FMS- and healthy controls. Anhedonia scores were significantly elevated in
FMS+ compared to healthy controls. Pain ratings showed no main effect of condition (p=0.6)
and no interaction of group x condition effect (p=0.9). The between-subject-factor group
reached significance F(2,37)=16.6, p<0.001. Gabriel post hoc tests indicated significant
greater pain ratings in FMS + patients compared to healthy subjects and FMS- patients and
between healthy subjects and FMS- patients.
ROI analysis
Mean regional binding potential (BPND) values for each condition and mean changes
in BPND between conditions and ǻBP are presented in Table 5. Plot of mean percentage
change in binding potential (¨BP) in the ROI analyses are shown in Figure 13.
Significance of ¨BP in each region and each group
One-sample t-tests yielded statistically significant differences (Bonferroni corrected)
between mean percentage changes in binding potential and the assumed null value in all
regions of interest. Left putamen t =11.878, SEM = 16.335, p<0.001 (two-tailed); right
putamen t = 8.007, SEM = 15.23918, p< 0.001 (two-tailed); left ventral striatum t = 2.963,
SEM = 10.97483, p= 0.005 (two-tailed); right ventral striatum t = 7.985, SEM = 16.65482, p<
0.001 (two-tailed); left caudate nucleus t= 3.316, SEM= 13.67215 p= 0.002 (two-tailed); right
caudate nucleus t= 10.059 , SEM = 16.92849, p<0.001; left nucleus accumbens t= 2.616,
SEM= 13.05666, p= 0.013 (two-tailed) , right nucleus accumbens t= 12.055, SEM= 29.95337,
p<0.001 (two-tailed). One-sample t-tests yielded statistically significant differences
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(Bonferroni corrected) between mean percentage changes in binding potential and the
assumed null value in all groups t=6.400, SEM=0.820, p<0.001 (two-tailed).
Baseline group differences
No baseline group differences in striatal D2/3 receptor availability at rest between
FMS+ and FMS- patients compared to healthy controls have been found as described in a
companion paper (Ledermann et al. under review).
Group differences for ¨BP in the collapsed FMS group
Considering all FMS participants together in a group significant reductions in BPND in
the reward vs. the control condition in the right nucleus accumbens F(1,39)=5.98 p=0.019
were found and the ǻBP was significantly greater in FMS patients compared to healthy
controls (collapsed FMS group).
Group comparison for ǻBP (separating between FMS+ and FMS-)
We  found  significant  effects  on  ¨BP  in  right  caudate  nucleus  (p=0.024) in all
participants. Post-hoc test Gabriel showed that mean ¨BP was significantly greater in FMS+
compared to FMS-, but not between controls and FMS+ resp. FMS-. The mean ¨BP in the
right nucleus accumbens differed significantly between groups (p=0.013). Post-hoc test
Gabriel  showed  that  mean  ¨BP  was  significantly  greater  in  FMS+  compared  to  healthy
controls but no significant group difference was found for the FMS- group.
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Influence of region and laterality
The repeated measures ANOVA with factors region and laterality and between-
subjects factor group showed significant main effects for region F(1,37)=7.7, p<0.008 and
laterality F(1,37)=6.07, p=0.018. The interaction between region and laterality was significant
F(1,37)=9.3, p<0.004. The between subject factor group did not reach significance
F(2,37)=1.1, p=0.333.
Correlations between depression, anhedonia, anxiety and pain disability scores with
ǻBP during sensorimotor control and reward condition
No significant correlations were found in regions showing significant changes in [11C]
raclopride binding. However, the only significant correlations were a significant correlation
between ǻBP in the left nucleus accumbens and SHAPS ( r= 0.56, p<0.045) and a trend for a
negative correlation between ǻBP in the left nucleus accumbens and PDI (r=-0.54, p=0.057)in
the group of FMS- patients. No other significant correlations could be found.
Discussion
In this study, we investigated endogenous DA release during unpredictable monetary
rewards in FMS patients with and without co-morbid depression and age- and gender-
matched healthy subjects. Using the [11C] raclopride Bolus- plus-infusion PET method and a
validated slot-machine task, we surprisingly found a greater percentage of displacement of
[11C] raclopride in the right nucleus accumbens by endogenuously released DA in all FMS
patients that was more accentuated in patients with co-morbid depression. FMS patients with
co-morbid  MDD  compared  to  healthy  controls.  Moreover,  FMS  patients  with  co-morbid
depression showed greater reductions in [11C] raclopride binding in the reward vs. the
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sensorimotor  conditions  in  the  right  nucleus  caudate  compared  to  FMS  patients  without
depression. In sum these results suggest: 1) that FMS patients have a dysfunctional
neurochemical response to reward information; 2) that unpredictable monetary rewards elicit
an increased DA reaction in the controls and the FMS patients, which was more accentuated
in the patients; and 3) that the dysfunctional reward circuitry could be associated with co-
morbid depression in the pathology of FMS. Behaviourally, FMS patients had elevated
depression and pain scores, and FMS patients with co-morbid depression showed evidence of
anhedonia, the inability to experience pleasure. No significant correlations between regions
showing differences in DA release and depression, anhedonia and pain scores could be
determined. Pain ratings during the task were greater in all FMS patients, but there was no
evidence of decreased pain intensity following unpredictable rewards as has been shown
previously for appetitive stimuli (Rhudy, Williams, McCabe, Nguyen, & Rambo, 2005;
Rhudy, Williams, McCabe, Rambo, & Russell, 2006). These observed reductions in binding
potential could reflect differences between groups in the neural processing of obtaining
rewards. [11C] raclopride is sensitive to competition from endogenously released dopamine in
response to tasks that induce dopamine release. In this study, the observed decreases in
binding potential are, therefore, likely secondary to dopamine release in response to
unpredictable monetary rewards obtained in the slot-machine task. However, DA has been
shown not to be responsible for the processing of rewarding stimuli per se, but specifically for
the motivation to obtain rewards (Barbano & Cador, 2007; Berridge, 2007). Previous studies
reported decreased reward sensitivity and/or decreased motivation in rats with neuropathic
(Ozaki et al., 2002) and arthritic pain (Ji et al., 2010; Pais-Vieira, Mendes-Pinto, Lima, &
Galhardo, 2009). Furthermore, impaired decision making based on reward and punishment in
patients with chronic back pain and complex regional pain syndrome (CPRS) (Apkarian et al.,
2004), impaired operant learning of pain sensitization and habituation in FMS (Becker et al.,
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2011) and reduced reward/punishment signaling in FMS in the ventral tegmental area (Loggia
et al., 2014) have been reported. Although previous PET [11C]  raclopride  studies  of  DA
release during reward processing did not involve chronic pain patients or FMS patients, our
findings are partly compatible with their results. Martin-Soelch et al. (2011), using the same
method in a group of healthy subjects, found the strongest [11C] raclopride decrease in
response to unpredictable rewards in the right nucleus accumbens (Martin-Soelch et al.,
2011). Furthermore, associations between DRD3Ser9Gly polymorphism and DA release in
response to unpredictable rewards in the right nucleus accumbens in a sample of healthy
controls and patients with MDD were reported (Savitz et  al.,  2013).  This is  the same region
where we found significant differences between healthy controls and FMS patients with co-
morbid depression and between healthy controls and the whole FMS group. The differences
in the caudate nucleus are in line with a study of reward in MDD sharing differences in the
neural responses to reward in the caudate nucleus and nucleus accumbens (Pizzagalli et al.,
2009). However, this study and also other studies investigating MDD in reward tend to
indicate a decreased neural response to reward. In contrast, our findings in FMS patients with
co-morbid MDD are at odds with studies delineating striatal response to reward in individuals
with  MDD  (Dichter,  Kozink,  McClernon,  &  Smoski,  2012;  Forbes  et  al.,  2009;  Nestler  &
Carlezon, 2006; Pizzagalli et al., 2009; Stoy et al., 2012; Zhang, Chang, Guo, Zhang, &
Wang, 2013). They typically found lower levels of striatal response in individuals with MDD
compared to individuals without MDD. These findings indicate a loss of reward function that
drives symptoms such as anhedonia. The presence of accentuated striatal DA response in our
FMS patients with co-morbid MDD is therefore unexpected as depression, chronic pain and
anhedonia have been found to be associated with low responsiveness to reward cues
(Dawkins, Powell, West, Powell, & Pickering, 2006; Nutt et al., 2007). However, one
possible explanation for these findings might be that the responsiveness of the phasic DA
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system is regulated by tonic (extrasynaptic) DA levels. Tonic DA levels are modulated by
presynaptic limbic and cortical glutamatergic inputs as well as DA neurons in the ventral
tegmental area (VTA) (Grace, 1991; Howland, Taepavarapruk, & Phillips, 2002) and low
tonic DA levels facilitate phasic DA firing (Grace, 1991). This fits well with reports of DA
hypofunction in FMS in particular with reduced presynaptic DA activity in limbic cortex and
VTA (Wood, Patterson, et al., 2007; Wood, Schweinhardt, et al., 2007). Furthermore, low
levels of DA in the central DA system are experienced as aversive (De Witte, Pinto, Ansseau,
& Verbanck, 2003) and increased DA activity is associated with pleasurable affective states
(Ashby, Isen, & Turken, 1999). It is therefore conceivable that the attenuated DA reaction in
our FMS patients is due to an up-regulation of the mesolimbic DA system stemming from an
under activation of striatal and prefrontal DA projections in the mesolimbic DA system.
In addition, these results might also have important implications for understanding the
specificities of FMS subgroups according to depressive symptoms and individuals with MDD.
While FMS and MDD have been shown to share common features both at physiological and
psychological levels (for review see (Gracely, Ceko, & Bushnell, 2012)), our results suggest
that FMS and MDD are related to different pathophysiological mechanisms on a
neurobiological level.
In sum, these findings add to the growing body of literature supporting the notion of
the mesolimbic DA system dysfunction in the pathophysiology of FMS. Our results are in line
with other studies showing altered dopaminergic neurotransmission in FMS patients. For
instance, recent PET studies have demonstrated that FMS patients exhibit reduced activity
levels of DOPA decarboxylase, an enzyme involved in dopamine metabolism, in several
regions including the ventral tegmental area (Wood, Patterson, et al., 2007). Reduced
dopaminergic brain responses to evoked pain have been reported in FMS patients compared
to healthy controls (Wood, Schweinhardt, et al., 2007). A recent fMRI study reported reduced
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reward/punishment signaling in FMS in the ventral tegmental area (Loggia et al., 2014). Our
findings extend prior reports of alterations of pain reward interactions with chronic pain
(Becker et al., 2012; Loggia et al., 2014) and suggest that there are differences between FMS
patients with and without co-morbid MDD on a neurobiological level. In chronic pain the
process of a reward deficit syndrome may relate to ongoing circuit dysfunction as increasing
evidence suggests that plasticity of neural circuits are responsible for subtle changes over
time, contributing to the behavioral manifestation of altered affective processes including
blunting of reward or enhancing depression.
Strengths and limitations
To the best of our knowledge, this is the first study to investigate the dopaminergic
response to unpredictable rewards in patients with FMS and no study so far addressed the
question of the common neural basis of pain, reward processes and underlying depression in
FMS. One strength of the current study is the relatively large number of FMS subjects who
completed the study. This allowed comparing FMS patients with and without co-morbid
depression systematically on the basis of standardized diagnostic methods. Furthermore, by
using the [11C] raclopride Bolus-plus-infusion PET method and a validated slot-machine task,
we were able to measure endogenous DA release in vivo in response to unpredictable
monetary rewards.
Several limitations of our study design merit comment. First, patients were allowed to
continue their medication. Recent evidence suggests that SSRIs can reduce striatal activation
under reward conditions, whereas drugs that impact on the norepinephrine system accentuate
this response (McCabe, Mishor, Cowen, & Harmer, 2010). Second, the phase of menstrual
cycle in which female subjects were examined was not fixed and we did not evaluate
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differential effects of distinct menstrual phases on reward-induced DA release. However, 28
of the participants were post-menopausal.
Conclusions
The current study identified differences in endogenous DA release during
unpredictable monetary rewards in FMS patients with and without co-morbid depression and
age- and gender matched healthy subjects. In sum, FMS patients exhibited dysfunctional DA
responses to unpredictable monetary rewards relative to healthy controls. However, the
finding of an increased response to rewarding stimuli in FMS patients with co-morbid
depression is new. Our findings extend previous research on impairments of chronic pain in
several aspects of reward processing and show that FMS patients with co-morbid depression
may be distinguished from those without depression on a neurobiological level. Further, we
found that FMS patients with MDD exhibited different DA release patterns than patients with
MDD. These findings have important implications for identifying both common and distinct
properties of the neural circuitry underlying FMS with and without co-morbid MDD and
provide important insights toward a better understanding of the etiology of this prevalent and
debilitating disorder. Moreover, these findings suggest that interventions to restore DA
regulation could be therapeutically beneficial in FMS patients.
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Figure 12. Illustration  of  the  experimental  task  adapted  from  (Martin-Soelch  et  al.  2011)
During each trial, subjects were presented four distinct pictures (apple, grape, cherry, bell)
presented in a “slot-machine” motif. Subjects were asked to choose one of the four with a
button press on a four-button response box using the right hand. This response was followed
by a 0.5 second delay. In the rewarded trials a 1 SFr. coin appeared for 1 second and subjects
heard the characteristic sound of an opening cash-register door. These monetary gains were
provided in a pseudo-randomized order with an average of one reward per every fourth trial.
In the sensorimotor control trials, subjects instead were presented a meaningless symbol
accompanied by a “click” sound on every fourth trial. After receiving the trial outcome
subjects were presented their running total of earnings for 1 second. Displaying the actual
balance account prevented rapid discounting of the rewards presented. At the end of each trial
subjects viewed a blank screen for 1 second. During the reward task subjects were unaware of
which trial or picture would lead to the receipt of a reward, except that the same picture could
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not provide a reward in two consecutive trials. Subjects thus were instructed not to select the
same picture  more  than  twice  in  a  row (selection  of  the  same picture  twice-in-a-row led  to
interruption of the task, and the task continued only after another picture was selected). In the
sensorimotor control condition the subjects performed the task without receiving any reward,
and in the monetary reward condition the subjects received monetary rewards in an
unpredictable fashion.
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Figure 13. Reward-related changes in regional binding potentials for [11C]
raclopride. Plot of mean percentage change in binding potential (¨BP) in the
ROI analyses. A significant group difference was evident in the right caudate nucleus and the
right nucleus accumbens. Post-hoc tests indicated a significant difference in ¨BP between
FMS+ and FMS- patients in the right caudate nucleus and between healthy controls and
FMS+ in the right nucleus accumbens. PutL, left putamen; PutR, right putamen; VSTL, left
ventral Striatum; VSTR, right ventral striatum, CNL, left caudate nucleus; CNR right caudate
nucleus, NAL, left nucleus accumbens; NAR right nucleus accumbens
Figure 12 Reward-related changes in regional binding potentials for [11C]
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Table 5
Mean pain ratings during PET measurement for each condition for subjects with Fibromyalgia (FMS without MDD N=13), (FMS with MDD N=11) and
healthy controls (N=17)
Tabelle 5 Mean pain ratings during PET measurement
FMS without MDD FMS with MDD Healthy controls p-value
Sensorimotor
condition
Mean (SD)
Reward
condition
Mean (SD)
Sensorimotor
condition
Mean (SD)
Reward
condition
Mean (SD)
Sensorimotor
condition
Mean (SD)
Reward
condition
Mean (SD)
Pain rating 2.91 (1.24) 2.83 (0.93) 3.18 (0.98) 3.09 (0.7) 1.29 (0.98) 1.29 (0.98) 0.01*
*level of significance two-tailed p<0.05 for the between subject-factor group in the repeated measures ANOVA for pain ratings during the PET measurement
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Table 6
Mean regional binding potential (BPND) values for each condition and mean changes in BPND between conditions for subjects with Fibromyalgia (FMS
without MDD N=13), (FMS with MDD N=11) and healthy controls (N=17)
Tabelle 6 Mean regional binding potential values for each condition and mean changes in binding potential between conditions for subjects with FMS
;ȴ ;ȴ ;ȴ
*Levels of significance (two-tailed) are given for the ANOVA for the between group comparisons of ǻBP
1 left 2 right
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5. General discussion
Converging evidence from preclinical, epidemiological, neuroimaging and genetic
studies points to a role for DA neurotransmission in modulating pain perception and analgesia
(Jarcho et al., 2012; Wood, 2008). Further, findings suggest that pain and reward are mediated
by similar neural pathways in the CNS involving a complex network of subcortical and
prefrontal structures related to both the DA and the opioid systems that influence each other
on a neurobiological and motivational level (Borsook et al., 2007; Kut et al., 2011; Leknes &
Tracey, 2008). An involvement of DA in the processing of rewarding information is well
documented (Haber & Knutson, 2010). Recent findings suggest that pain, in particular long-
term pain, might impair several aspects of reward processing (Becker et al., 2012; Loggia et
al., 2014). It has been suggested that a dysregulation in DA signaling may modulate the
experience of pain both directly, by enhancing or diminishing the propagation of nociceptive
signals, and indirectly, by influencing affective and cognitive processes that affect the
expectation, interpretation and experience of nociceptive signals (Jarcho et al., 2012).
However, to date, the exact role of DA in anti-nociception and pain perception remains
essentially unknown. Prior research has evidenced a dysfunction of the central DA system in
chronic pain patients, including higher DA D2 receptor availability in patients with
neuropathic pain and reduced presynaptic D2 receptor availability in patients with FMS
(Hagelberg, Forssell, Aalto, et al., 2003; Hagelberg, Forssell, Rinne, et al., 2003; Wood,
Patterson, et al., 2007).
Thus, the aim of this study was to investigate the modulation of pain perception by DA
in  FMS  patients  compared  to  healthy  controls  using  the  [11C] raclopride PET method. A
second aim was to investigate whether the DA response to rewarding stimuli could
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differentiate between FMS patients with and without co-morbid depression in order to better
understand the depressive symptoms often associated with FMS.
This thesis focuses on two reports referring to DA activity, pain perception and reward
processes in patients with FMS. In the first report, basic DA D2/D3 receptor availability and
subjective ratings of pain related to the administration of painful thermal stimulation were
explored in order to examine whether FMS patients would differ in D2/D3 receptor
availability and its association with individual pain perception from healthy subjects. The
second report aimed at investigating endogenous DA release associated with unpredictable
monetary  rewards  to  examine  whether  FMS  patients  with  and  without  depression  differ  on
their DA response to unpredictable reward.
The findings of each individual report have been discussed in the specific discussion
section of the relevant report. In the following, the findings are briefly summarized and
discussed in greater detail to disclose their implications for the role of DA in pain perception
and reward processes in FMS. Furthermore, methodological issues and limitations of the
study will be discussed, followed by the clinical relevance of our findings and a consideration
of future research steps.
Summary of results
While the first study of this thesis examined striatal D2 receptor availability at rest and
associations between D2 receptor availability and individual pain perception, the second study
investigated striatal DA transmission in response to unpredictable rewards.
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Report 1: Relation of Dopamine Receptor 2 Binding to Pain Perception in Female
Fibromyalgia Patients with and without Depression – a [11C] raclopride PET-study
Given that DA has been hypothesized to have a role in pain perception, specifically
anti-nociception, we were particularly interested in the striatal D2/D3 receptor availability of
FMS patients and its associations with individual pain perception. Therefore, 17 healthy
controls and 24 FMS patients (11 with co-morbid MDD) underwent a PET [11C] raclopride
scan to determine D2/D3 receptor availability at rest. We expected FMS patients to show
reduced [11C] raclopride binding in striatal regions compared to healthy controls, reflecting a
decreased postsynaptic availability of D2/D3 receptors in these patients. We expected the
reduction to be more pronounced in FMS patients with co-morbid MDD than in FMS patients
without MDD. Additionally, we aimed to test the association between pain sensitivity and
striatal D2/D3 receptor binding with regard to the role of comorbid MDD. Outside the
scanner, subjects were asked to rate painful heat stimuli applied cutaneously on their right
volar forearm with a contact thermode. Pain thresholds, ratings of pain intensity during and
after painful stimulation were recorded. Individual response characteristics to pain were
determined using components from the Signal Detection Theory (Clark, 1966). We compared
the discriminative capacity, i.e. the individual’s capacity to discriminate between lower and
higher  pain  intensities,  and  the  response  criterion,  i.e.  the  subject’s  tendency  to  report  pain
during noxious stimulation due to psychological factors.
Unexpectedly, we did not find any differences in D2/D3 receptor availability at rest
between FMS patients with and without co-morbid depression and healthy controls. Our
findings are at odds with an evaluation of dopaminergic function in FMS patients using 6-18F
fluoro-L-DOPA PET which revealed reduced presynaptic DA synthesis as indicated by
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reduced fDOPA uptake in several pain-related brain regions, including the thalamus,
mesencephalon, insula, ACC and hippocampus (Wood, Patterson, et al., 2007).
It is possible that these previous findings were influenced by methodological
differences, i.e. pre-synaptic versus post-synaptic measures could explain these contradictory
results. Furthermore, the reductions in 6-18F  fluoro-L-DOPA  uptake  were  limited  to
mesencephalon including VTA and substantia nigra, suggesting that presynaptic neuronal
integrity in the mesencephalon is a more sensitive indicator of FMS than postsynaptic
receptor sites. Moreover, these studies included smaller samples of patients and did not
control for depression or other co-morbid disorders. Additionally, lower raclopride BP in
FMS patients than healthy controls in all functional sub-regions of the striatum during non-
painful saline infusion have been reported (Wood, 2008). However, it is not entirely clear if
this result reflects decreased DA receptor density or a greater release of DA in response to
non-painful saline infusion and is therefore not directly comparable to our experimental
paradigm. No other study so far has addressed DA changes at the post-synaptic level in FMS
(i.e. in the absence of noxious stimuli).
The results from the correlational analysis between D2/D3 receptor availability and
psychophysical results suggest a potential link between D2/D3 receptor availability and pain
perception due to psychological factors in FMS which differ however between patients with
and without co-morbid depression corresponding with the assumption of an involvement of
emotional and psychological processes (Geisser et al., 2003; Staud, 2004) and affect (Staud,
2004; Staud et al., 2003) in the promotion of pain in these patients. Additionally, our
psychophysical results (thermal pain threshold, response criterion) support the idea of a more
pronounced deficit in pain inhibition in FMS with co-morbid depressive symptoms,
suggesting that depression could influence pain perception in FMS via DA.
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Report 2: Increased dopamine release to unpredictable rewards in female
Fibromyalgia patients with comorbid depression - a [11C] raclopride bolus plus
infusion PET study
In  the  second  report,  we  investigated  endogenous  DA  release  associated  with
unpredictable monetary rewards during B/I [11C] raclopride PET scanning using a validated
reward task (Martin-Soelch et al., 2011) in FMS patients with and without co-morbid MDD
and healthy controls to investigate if FMS is associated with dysfunctions of the central
reward system. We postulated that the healthy controls would evidence an increase of striatal
DA transmission in response to unpredictable reward and that this increase would be reduced
in  FMS  patients.  Furthermore,  we  expected  FMS  patients  with  co-morbid  MDD  to  show  a
stronger reduction of this effect than FMS patients without co-morbid MDD. Surprisingly, we
found a greater percentage of displacement of [11C] raclopride in the right nucleus accumbens
by endogenously released DA in FMS patients with co-morbid MDD compared to healthy
controls. Moreover, FMS patients with co-morbid depression showed greater reductions in
[11C] raclopride binding in the reward vs. sensorimotor control condition in the right nucleus
caudate compared to FMS patients without depression. Overall, considering the entire FMS
group, we found greater reductions in [11C] raclopride binding in the reward vs. sensorimotor
control condition in the right nucleus accumbens in FMS patients compared to healthy
controls. Furthermore, when comparing FMS patients with MDD and MDD patients, studies
with  MDD  patients  showed  markedly  different  responses  to  monetary  rewards,  with  the
majority in these studies indicating hypoactivity in the ventral striatum (Diener et al., 2012;
Greening, Osuch, Williamson, & Mitchell, 2014). Reasons for hyperactive DA reaction in
FMS patients are very speculative and could involve an intrinsic hyper-reactivity of midbrain
DA neurons (i.e. heightened phasic midbrain DA neuron burst firing to potentially rewarding
stimuli) or to diminished regulatory control of nucleus accumbens dopaminergic function
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stemming from a more widespread failure of inhibitory mechanisms (e.g. dysregulation of
inhibitory afferents to the VTA) or due to an upregulation of the mesolimbic DA system
stemming from an underactivation of striatal and prefrontal DA projections in the mesolimbic
DA system. However, conclusive statements cannot be made at this point as our study did not
include any DA pharmacological manipulation. Taken together, these results suggest that
unpredictable monetary rewards elicit an increased DA reaction in FMS patients being
indicative for dysfunctional reward processing in FMS and that dysfunctional reward circuitry
could be associated with co-morbid depression in the pathology of FMS. This is the first study
identifying differences in endogenous DA release during unpredictable monetary rewards in
FMS patients with and without co-morbid depression and age- and gender matched healthy
subjects. Our findings extend previous research on impairments of chronic pain in several
aspects of reward processing (Becker et al., 2012) and suggest that FMS patients with co-
morbid MDD may be distinguished from healthy subjects and that depression may reinforce
this effect.
Methodological considerations and limitations
There are a few methodological issues worth mentioning: first, the results in Report 1
did not allow for differentiation between D2/D3 receptor density or intrasynaptic DA
concentration and the interpretation of underlying neuronal factors should be treated with
caution. Prior work indicates that [11C] raclopride values from the bolus method are almost
identical to binding values generated by a bolus-infusion method, in which DA release can be
indirectly measured for the same subjects (Carson et al., 1997; Watabe et al., 2000). Secondly,
although SPM analysis of PET ligand studies is a viable alternative to ROI analysis,
especially for the exploration of changes without a priori region definitions, requirements of
the analysis include transformation of the PET data to standard anatomical space, smoothing
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of the data and quantitative normalization to account for global effects. In a small cohort as in
our study, these processes may reduce the sensitivity to subtle changes in raclopride binding.
Standardization  of  the  basal  ganglia  anatomy  for  SPM  analysis  is  a  known  challenge  (in
comparison to cortical anatomy). Therefore, our individual anatomy MR-based VOI analysis
may be considered as better accounting for individual basal ganglia anatomy and improving
the sensitivity of our PET measurements. Further, it could be argued that the painful stimuli
should directly be administered in the scanner to directly determine the link of D2/D2
receptor availability with individual pain perception. However, correlating subjective ratings
outside the scanner with PET measures is a standard method in PET designs in general and in
the investigation of pain modulation with PET in particular (Hagelberg et al., 2002;
Pertovaara et al., 2004). Finally, DA receptor binding results as well as individual responses
to pain may have been biased by the participant’s medication, which possibly influenced the
testing procedures, including slower reaction times and anti-nociceptive effects of
antidepressants. Nevertheless, we found significant differences between FMS patients and
healthy subjects with regard to the estimation of pain thresholds, and a previous study found
no significant group difference concerning SSRI medication regarding all pain thresholds
(Klauenberg et al., 2008). Furthermore, this aspect might also affect the findings in Report 2.
Recent evidence suggests that SSRIs can reduce striatal activation under reward conditions,
whereas drugs that impact the norepinephrine system accentuate this response (McCabe et al.,
2010). While inclusion of those taking concomitant medications might complicate
interpretation of results, one could counter that by so doing it was possible to enroll
individuals with more severe FMS symptoms. Moreover, the phase of the menstrual cycle
was not fixed and we did not evaluate differential aspects of distinct menstrual phases on
reward-induced DA release. However, 28 of the participants were post-menopausal. Finally,
as  the  PET  [11C] raclopride B/I approach permits imaging in only two conditions per scan
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session, we did not measure BPND in a resting state. Thus the effect of condition observed in
our analysis is specific to the reward condition vs. the sensorimotor control condition.
Another limitation of this line of research is that we used responses to monetary rewards.
Future research is needed to delineate linkages between laboratory measures of reward
processing and real life experiences of incentive motivation, positive affect, and reward-
seeking.
General discussion of the results
These data implicate DA as an important neurochemical moderator of differences in
individual pain perception in FMS patients with and without co-morbid depression, and
demonstrate enhanced functional engagement of the mesolimbic DA system in response to
reward. The findings observed in these two reports are consistent with several lines of
evidence supporting a role for disturbed dopaminergic neurotransmission contributing to
clinical pain in various chronic pain conditions including FMS (Hagelberg, Forssell, Aalto, et
al., 2003; Hagelberg et al., 2004; Wood, Patterson, et al., 2007). While several studies have
outlined a role for DA in nociception, the precise role of DA in human pain processing has
not been completely understood. It has been hypothesized that DA has direct anti-nociceptive
effects (Jarcho et al., 2012; Potvin et al., 2009; Wood, 2008), however recent studies suggest
a modulating role of DA in pain perception. It has been suggested that DA modulates the
salience  of  a  pain  stimulus  and  coping  response  (Becker  et  al.,  2013)  and  also  the  affective
component of pain. Rather than having direct anti-nociceptive effects, DA may, thus,
influence the motivation to endure or avoid pain, respectively (Becker et al., 2013) thus it is
feasible that this bias towards enduring or avoiding pain is subserved by a modulation of the
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affective component of pain perception, while the sensory-discriminative aspect remains
unaffected.
A role for DA in pain affect has been suggested by the large anatomical and functional
overlap between DA rich brain areas and areas involved in the processing of pain affect
(Jarcho et al., 2012; Potvin et al., 2009). The insula and ACC in particular have been shown to
receive mesolimbic DA projections as well as be involved in the affective aspects of pain
(Jarcho et al., 2012; Potvin et al., 2009).
Recent evidence has linked pain and reward processing in the human brain, suggesting
that DA might be involved. Additionally, FMS shares a common neurobiological
characteristic, namely altered functional output of striatal DA systems mediating the
processing of rewards with a range of psychiatric (i.e. substance-use disorders, affective
disorders, eating disorders, and obsessive compulsive disorders) neurodevelopmental
disorders (i.e. schizophrenia, attention-deficit/hyperactivity disorder, autism spectrum
disorders) and genetic syndromes (i.e. Fragile X syndrome, Prader-Willi Syndrome) (Dichter,
Damiano, & Allen, 2012). Therefore, DA-mediated reward-system dysfunction should be
considered a potential common etiologic factor in a range of conditions. Future research could
be aimed at understanding linkages between those diseases and reward function.
Perspective
With  the  studies  presented  here,  we  were  able  to  fill  gaps  in  the  current  knowledge
related to the role of DA in pain perception and reward processes in FMS. However, these
findings give rise to new research questions. A lot of unanswered questions remain about how
DA contributes to nociception and how chronic pain impairs reward processing, which should
be addressed in future studies.
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Hence, this thesis is intended to highlight initial evidence of the relevance of DA to
FMS  while  it  is  still  not  clear  exactly  how  DA  modulates  pain  perception  in  FMS.
Pharmacological challenges remain to elucidate the context of DA’s role in nociception.
Further studies should also take into account both healthy persons and FMS patients. Clearly
future studies are needed to address other chronic pain syndromes as well (e.g. neuropathic
pain syndromes) and additionally in relation to other brain circuits and neurotransmitters.
The  mesolimbic  DA  system  represents  only  one  component  of  a  very  complex  and
integrated set of circuits, and although DA is clearly a crucial neurotransmitter in the reward-
processing systems, there are multiple brain regions not addressed here that contribute to
reward processing, including the subthalamic nucleus, ventral pallidum, and lateral habenula
(McGinty et al., 2011).
[11C] raclopride has only moderate affinity for D2-like DA receptors, limiting its
utility to assessments of the striatum where the density of D2 receptors is high. To overcome
the above mentioned restriction to study the striatum, other brain regions compromising the
DA system, including cortical and limbic structures engaged in subjective experience of pain,
can now be addressed by more recently developed radiotracers, such as [18F] fallpride
(Woodward et al., 2009) or [11C] and FLB-457 (Narendran et al., 2011), which have higher
affinities for D2 receptors.
Furthermore, the vast majority of clinical research into reward-circuitry function in
chronic pain is cross-sectional in nature and focused only on adults. Therefore we cannot
draw any conclusions thus far about whether the dysfunctional reactions towards rewarding
stimuli were pain-induced or represent a predisposition and maybe even an increased
vulnerability for developing FMS. However, there might be critical periods during
development when predispositions to any pain disorders might occur, and understanding the
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factors that mediate these processes will be essential for treatment and the prevention of
symptom  onset.  Therefore,  longitudinal  analyses  are  necessary  to  disclose  causality,  and
examine if differences in reward circuit and therefore neurotransmission may have preceded
FMS.
It remains an open question if the observed enhancement in endogenous DA release in
response  to  monetary  rewards  is  a  characteristic  of  FMS  or  whether  this  enhanced  DA
reaction also occurs in other pain syndromes or diseases related to stress.
Regarding the clinical implications of the present findings, treatment options involving
dopaminergic parameters might be considered. Dopaminergic agents represent supportive
preliminary evidence for restoring DA regulation that could be therapeutically beneficial in
FMS patients (Becker & Schweinhardt, 2012). The results of report 1 support the notion that
psychological therapies might hold potential as a useful modality in the multidimensional
treatment of fibromyalgia. Previous studies reported psychological pain management skills as
efficacious in FMS with Cognitive behavioral therapy (CBT) outperforming other
psychological treatments in short-term pain intensity reduction (Vlaeyen et al., 1996). Given
that FMS is still difficult to treat, investigations of reward-circuitry functioning may have
implications for clinical practice and open new treatment options for FMS.
The results of report 2 imply therapies such as e.g. mindfulness-based interventions
such as the mindfulness based stress reduction program (MBSR) (Kabat-Zinn et al., 1998).
This program widely used for the treatment of chronic pain conditions (Chiesa & Serretti,
2011) and might be a non-pharmacological treatment option restoring the functionality of the
reward system as this intervention has been shown to be associated with an increased
experience of momentary positive emotions as well as greater appreciation of, and enhanced
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responsiveness to, pleasant daily-life activities (Geschwind et al., 2010; Segal, Vincent, &
Levitt, 2002).
More recently, Mindfulness-Oriented Recovery Enhancement (MORE), a new
multimodal intervention designed to address chronic pain, craving and opioid misuse
behaviours integrating training in savouring natural rewards with mindfulness training has
been shown to decrease pain severity and enhance natural reward processing in chronic pain
patients (Garland, 2014; Garland, Froeliger, & Howard, 2014).
Furthermore, deep brain stimulation, a neurosurgical technique involving the
implantation of electrodes in the brain for modulation of pathological neural activity, has been
shown to normalize striatal reward function in depression and eating disorders (Pizzagalli,
2011). This method could possibly provide an opportunity to normalize the striatal reward
function in FMS.
Finally, poorly defined conditions such as FMS could benefit from objectively
measurable biomarkers that could be used to verify the diagnosis of FMS, identify subgroups
of  FMS  patients  or  to  follow  disease  progress.  Therefore,  enhancement  in  endogenous  DA
release in response to monetary rewards as observed in our FMS patients that differed
between patients with and without co-morbid MDD could present a promising target.
Conclusion
Together, our data add to the mounting evidence for a disruption of normal
dopaminergic neurotransmission in the pathophysiology of FMS as described by Wood and
Holman (2009) ”as an elephant among us waiting to be noticed as it occupies an increasing
amount of floor space in the vault of our knowledge regarding FMS” (Wood & Holman,
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2009). Further progress in our understanding and management of this disorder requires a
better understanding of dopaminergic neurotransmission and therapeutic strategies aimed at
manipulating dopaminergic parameters as a relevant approach for the treatment of this
disorder.
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